Dual ATM and DNA-PK inhibitors for use in antitumor therapy

Compounds targeting ATM and DNA-PK kinases enhance radiation sensitivity in cancer cells, improving tumor control and reducing side effects by selectively inhibiting these kinases, thus addressing the limitations of current radiosensitizers.

JP7595959B2Active Publication Date: 2024-12-09XRAD HOLDING CAYMAN LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022505550
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-08-06
Filing Date
2020-07-30
Publication Date
2024-12-09
Estimated Expiration
2040-07-30

AI Technical Summary

Technical Problem

Current radiosensitizers for cancer treatment are less effective due to targeting nonspecific pathways, limiting the enhancement of radiation therapy's efficacy.

Method used

Development of compounds that selectively inhibit ATM and DNA-PK kinases, which are crucial for cellular response to DNA damage, enhancing radiation sensitivity in cancer cells.

Benefits of technology

The compounds increase the sensitivity of cancer cells to radiation therapy, allowing for improved tumor control with reduced side effects and lower radiation doses, and can be used in combination with chemotherapy or immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595959000086
    Figure 0007595959000086
  • Figure 0007595959000087
    Figure 0007595959000087
  • Figure 0007595959000088
    Figure 0007595959000088
Patent Text Reader

Abstract

Provided herein are compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein the substituents are as described herein. These compounds and their pharmaceutical compositions may be useful in the treatment of neoplastic diseases. [Formula 1] TIFF2022542285000079.tif45170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compounds and their pharma- ceutically acceptable salts, and methods of their use, for the treatment of cancer as monotherapy or in combination with radiation therapy, chemotherapy, and / or immunotherapy. [Background technology]

[0002] Several members of the PIKK (PI-3K-like kinase) family of serine-threonine kinases are known mediators of DNA damage signaling.

[0003] Radiation therapy (RT) is used to treat over 50% of all cancer patients at some point during their disease. Despite significant efforts, previous approaches to developing clinical radiosensitizers have been limited in effectiveness, primarily as a result of targeting non-specific pathways that are not direct regulators of the cellular response to radiation.

[0004] New therapies for neoplastic diseases are needed. Summary of the Invention

[0005] In general, the present invention provides a compound of formula (I):

[0006] [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, Z is CH, CR 3 , or N, Y is CHR 5 or NR 6 and n is 0, 1, 2, or 3; R 1 But -OLN(R 7 ) 2 or optionally substituted 4-membered saturated N-heterocyclyl; R2 is C1-3 alkyl; Each R 3 are independently halogen; R 4 is optionally substituted alkyl; R 5 is hydrogen, optionally substituted C 1-3 alkyl, or benzyloxy; R 6 is arbitrarily replaced by C 1-3 is alkyl, Each R 7 are independently H or optionally substituted C 1-3 is alkyl, Provided is a compound of formula (I), or a pharma- ceutically acceptable salt thereof, wherein L is optionally substituted ethylene.

[0007] In some embodiments, n is 1. In certain embodiments, the compound is a compound of formula (IA):

[0008] [ka] or a pharma- ceutically acceptable salt thereof.

[0009] In certain embodiments, R 3 is halogen (e.g., fluorine). In a further embodiment, n is 0.

[0010] In yet another embodiment, the compound is a compound of formula (IB):

[0011] [ka] or a pharma- ceutically acceptable salt thereof.

[0012] In a further embodiment, R 1 -OLN(R 7 In some embodiments, one R 7 is H, and the remaining R 7is optionally C 1-3 In certain embodiments, at least one R 7 is isopropyl. In certain embodiments, R 2 is methyl, ethyl, or isopropyl. In a further embodiment, R 2 is methyl. In yet another embodiment, R 4 In yet another embodiment, Y is CHR 5 In a further embodiment, R 5 is hydrogen. In other embodiments, R 5 is an arbitrarily substituted C 1-3 In yet another embodiment, R 5 In yet another embodiment, Y is NR 6 In some embodiments, R 6 is an optionally substituted C alkyl. In certain embodiments, R 6 is isopropyl.

[0013] In certain embodiments, the compound is

[0014] [ka] and pharma- ceutically acceptable salts thereof.

[0015] In a further embodiment, the compound has the structure:

[0016] [ka] or a pharma- ceutically acceptable salt thereof.

[0017] In yet another embodiment, the compound has the structure:

[0018] [ka] or a pharma- ceutically acceptable salt thereof.

[0019] In a further embodiment, the compound has the structure:

[0020] [ka] or a pharma- ceutically acceptable salt thereof.

[0021] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0022] In yet another aspect, the present invention provides a method for treating a neoplastic disease (e.g., cancer, e.g., a cancer described herein) by administering a therapeutically effective amount of a compound of the present invention, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition of the present invention to a patient in need thereof. In yet another aspect, the present invention provides a pharmaceutical composition for use in treating a neoplastic disease (e.g., cancer, e.g., a cancer described herein). The pharmaceutical composition comprises a compound of the present invention. In a further aspect, the present invention provides the use of a compound of the present invention in the manufacture of a medicament for treating a neoplastic disease (e.g., cancer, e.g., a cancer described herein). In some embodiments, the neoplastic disease is brain cancer, bladder cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gastrointestinal stromal tumor, gastric cancer, head and neck cancer, buccal cancer, oral cancer, hepatocellular carcinoma, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, salivary gland cancer, sarcoma, testicular cancer, urothelial carcinoma, vulvar cancer, or Wilms' tumor. In further embodiments, the neoplastic disease is breast cancer, lung cancer, head and neck cancer, pancreatic cancer, rectal cancer, glioblastoma, hepatocellular carcinoma, cholangiocarcinoma, metastatic liver lesion, melanoma, osteosarcoma, soft tissue sarcoma, endometrial cancer, cervical cancer, prostate cancer, or Merkel cell carcinoma.

[0023] In some embodiments, the patient is undergoing radiation therapy. In certain embodiments, the compound or pharmaceutical composition is administered to the patient simultaneously with radiation therapy. In certain embodiments, the compound or pharmaceutical composition is administered to the patient prior to radiation therapy. In further embodiments, the compound or pharmaceutical composition is administered to the patient after radiation therapy. In yet other embodiments, radiation therapy is administered externally, internally, brachytherapy, or whole-body exposure, e.g., to a radionuclide (e.g., a beta-emitting radionuclide (e.g., 32 Phosphorescence, 67 copper, 77 Bromin, 89 strontium, 90 yttrium, 105 rhodium, 131 Iodine, 137 cesium, 149 Prometheum, 153 samarium, 166 holmium, 177 lutetium, 186 rhenium, 188 Rhenium, or 199 gold), alpha-emitting radionuclides (e.g. 211 Astatine, 213 Bismuth, 223 radium, 225 Actinium, or 227 thorium), gamma-emitting radionuclides (e.g. 192 iridium), or electron capture radionuclides (e.g. 67 gallium, 103 Palladium, or 125 iodine), antibody-radionuclide conjugates (e.g., 90 Y-ibritumomab tiuxetan, 131 I-tositumomab, 225 Ac-lintuzumab tetraxetan, 227 Th-anetumab colixetan, 90 Y-epitumomab sitsukicetan, 90 Y-clivatuzumab tetraxetan, 177 Lu-rilotomabsatetraxetane, 90 Y-rosopatamab tetraxetan, 90 Y-tabituximab valzuxetan, or 90Y-tacatuzumab tetraxetane), or another targeted radionuclide conjugate (e.g. 131 I-PSMA, 90 Y-PSMA, 177 Lu-PSMA, or 177 Lu-sateotide tetraxetane). Preferably, the radiation therapy comprises administering an antibody radionuclide conjugate. In further embodiments, the patient is administered an anti-tumor agent. In other embodiments, the anti-tumor agent is one or more of cisplatin, oxaliplatin, carboplatin, barbicin, idarubicin, calicheamicin, or a PARP inhibitor. In still other embodiments, the anti-tumor agent is an anti-tumor biologic agent and / or an anti-tumor immunotherapeutic agent. In still other embodiments, the compound or pharmaceutical composition is administered to the patient simultaneously with the anti-tumor agent. In some embodiments, the compound or pharmaceutical composition is administered to the patient before the anti-tumor agent. In certain embodiments, the compound or pharmaceutical composition is administered to the patient after the anti-tumor agent. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] definition It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. Additionally, although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. In addition to the foregoing, as used in the specification and appended claims, unless specified to the contrary, the following terms have the meanings indicated: "Amino" refers to the -NH2 radical. "Cyano" refers to the -CN radical. "Hydroxyl" refers to the -OH radical. "Imino" refers to the =NH substituent. "Nitro" refers to the -NO2 radical. "Oxo" refers to the =O substituent. "Thioxo" refers to the =S substituent. "Trifluoromethyl" refers to the -CF3 radical.

[0025] "Alkyl" refers to a straight-chain, saturated, acyclic, monovalent hydrocarbon radical or a branched-chain, saturated, acyclic, monovalent hydrocarbon radical having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms or 1 to 6 carbon atoms, attached to the remainder of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Optionally substituted alkyl radicals include halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR, -O- ... 14 , -OC(O)-R 14 , -N(R 14 )2, -C(O)R 15 , -C(O)OR 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (t is 1 or 2), -S(O) t OR 16 (t is 1 or 2), -S(O) p R 16 (p is 0, 1, or 2) and -S(O) t N(R 14 t is 1 or 2; and each R 14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, or heteroaryl; each R 15 is independently hydrogen, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 16is independently alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl.

[0026] "Alkenyl" refers to a straight-chain, acyclic, monovalent hydrocarbon radical containing one, two, or three carbon-carbon double bonds, or a branched, acyclic, monovalent hydrocarbon radical having 2 to 12 carbon atoms, preferably 2 to 8 carbon atoms, which is attached to the remainder of the molecule by a single bond, e.g., ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like. Optionally substituted alkenyl radicals include halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR, -O- ... 14 , -OC(O)-R 14 , -N(R 14 )2, -C(O)R 15 , -C(O)OR 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (t is 1 or 2), -S(O) t OR 16 (t is 1 or 2), -S(O) p R 16 (p is 0, 1, or 2) and -S(O) t N(R 14 t is 1 or 2; and each R 14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 15 is independently hydrogen, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 16is independently alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclyl, or heteroaryl.

[0027] "Alkynyl" refers to a straight-chain, acyclic, monovalent hydrocarbon radical or a branched, acyclic, monovalent hydrocarbon radical having from 2 to 12 carbon atoms, preferably from 2 to 8 carbon atoms, containing one or two carbon-carbon triple bonds and optionally one, two, or three carbon-carbon double bonds, which is attached to the remainder of the molecule by a single bond, e.g., ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-1-en-4-ynyl, and the like. Optionally substituted alkynyl radicals include halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR, -O- ... 14 , -OC(O)-R 14 , -N(R 14 )2, -C(O)R 15 , -C(O)OR 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (t is 1 or 2), -S(O) t OR 16 (t is 1 or 2), -S(O) p R 16 (p is 0, 1, or 2) and -S(O) t N(R 14 )2, where t is 1 or 2; and each R 14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 15 is independently hydrogen, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 16is independently alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl.

[0028] "Alkylene" or "alkylene chain" refers to a straight, acyclic, saturated, divalent hydrocarbon chain or a branched, acyclic, saturated, divalent hydrocarbon chain having 1 to 12 carbon atoms, e.g., methylene, ethylene, propylene, n-butylene, etc. Alkylene chains are attached through single bonds. The points of attachment of the alkylene chains may be on the same carbon atom or on different carbon atoms within the alkylene chain. Optionally substituted alkylene chains include halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR, -O- ... 14 , -OC(O)-R 14 , -N(R 14 )2, -C(O)R 15 , -C(O)OR 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (t is 1 or 2), -S(O) t OR 16 (t is 1 or 2), -S(O) p R 16 (p is 0, 1, or 2) and -S(O) t N(R 14 t is 1 or 2; and each R 14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 15 is independently hydrogen, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 16is independently alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl. In some embodiments, alkylene is ethylene.

[0029] "Alkenylene" or "alkenylene chain" refers to a straight, acyclic, divalent hydrocarbon chain or a branched, acyclic, divalent hydrocarbon chain containing one, two, or three carbon-carbon double bonds and having 2 to 12 carbon atoms, e.g., ethenylene, propenylene, n-butenylene, and the like. Alkenylene chains are bonded through single bonds. The points of attachment of the alkenylene chains may be on the same carbon atom or on different carbon atoms within the alkenylene chain. Optionally substituted alkenylene chains include halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR, -O- ... 14 , -OC(O)-R 14 , -N(R 14 )2, -C(O)R 15 , -C(O)OR 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (t is 1 or 2), -S(O) t OR 16 (t is 1 or 2), -S(O) p R 16 (p is 0, 1, or 2) and -S(O) t N(R 14 t is 1 or 2; and each R 14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 15 is independently hydrogen, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R16 is independently alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl.

[0030] "Alkynylene" or "alkynylene chain" refers to a straight, acyclic, divalent, hydrocarbon chain or a branched, acyclic, divalent, hydrocarbon chain containing one or two carbon-carbon triple bonds and optionally one, two, or three carbon-carbon double bonds and having 2 to 12 carbon atoms, e.g., propynylene, n-butynylene, and the like. Alkynylene chains are bonded through single bonds. The points of attachment of the alkynylene may be on the same carbon atom or on different carbon atoms within the alkynylene chain. Optionally substituted alkynylene chains include halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR 14 , -OC(O)-R 14 , -N(R 14 )2, -C(O)R 15 , -C(O)OR 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (t is 1 or 2), -S(O) t OR 16 (t is 1 or 2), -S(O) p R 16 (p is 0, 1, or 2) and -S(O) t N(R 14 )2, where t is 1 to 2; and each R 14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 15 is independently hydrogen, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 16is independently alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl.

[0031] "Alkoxy" means a group of the formula -OR a where R a is an alkyl radical as defined above containing 1 to 12 carbon atoms. The alkyl portion of an optionally substituted alkoxy radical is optionally substituted as defined above for an alkyl radical.

[0032] An "alkoxyalkyl" is a group of the formula -R a -OR b where R is as defined above. a is alkylene, and R b is alkyl. The alkyl and alkylene portions of the optionally substituted alkoxyalkyl radical are optionally substituted as defined above for the alkyl radical and alkylene chain, respectively.

[0033] "Aralkyl" is a group of the formula -R a -R b where R a is alkylene, and R b is aryl. The alkylene and aryl portions of an optionally substituted aralkyl are optionally substituted as described herein for alkylene and aryl, respectively.

[0034] "Aryl" refers to an aromatic monocyclic or polycyclic hydrocarbon ring system radical containing 6 to 18 carbon atoms, with polycyclic aryl ring systems being bicyclic, tricyclic, or tetracyclic ring systems. Aryl radicals include, but are not limited to, fluorenyl, phenyl, and naphthyl. Optionally substituted aryl includes alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, aryl, heteroaryl, heteroarylalkyl, -R 15 -OR 14 , -R 15 -OC(O)-R14 , -R 15 -N(R 14 )2, -R 15 -C(O)R 14 , -R 15 -C(O)OR 14 , -R 15 -C(O)N(R 14 )2, -R 15 -N(R 14 )C(O)OR 16 , -R 15 -N(R 14 )C(O)R 16 , -R 15 -N(R 14 )S(O) t R 16 (t is 1 or 2), -R 15 -S(O) t OR 16 (t is 1 or 2), -R 15 -S(O) p R 16 (p is 0, 1, or 2), and -R 15 -S(O) t N(R 14 t is 1 or 2; and each R 14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 15 is independently a direct bond or a linear or branched alkylene or alkenylene chain, and each R 16 is independently alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclyl, or heteroaryl.

[0035] "Arylalkoxy" refers to a group of formula -OR, where R is aralkyl. Optionally substituted arylalkoxy is arylalkoxy optionally substituted as described herein for aralkyl. In some embodiments, arylalkoxy is benzyloxy.

[0036] "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical having 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, which may be saturated or unsaturated and is attached to the remainder of the molecule by a single bond. Polycyclic hydrocarbon radicals are bicyclic, tricyclic, or tetracyclic ring systems. Unsaturated cycloalkyls contain one, two, or three carbon-carbon double bonds and / or one carbon-carbon triple bond. Monocyclic cycloalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbornyl, decalinyl, and the like. Optionally substituted cycloalkyls include alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, oxo, aryl, aralkyl, cycloalkyl, heterocyclyl, heteroaryl, -R 15 -OR 14 , -R 15 -OC(O)-R 14 , -R 15 -N(R 14 )2, -R 15 -C(O)R 14 , -R 15 -C(O)OR 14 , -R 15 -C(O)N(R 14 )2, -R 15 -N(R 14 )C(O)OR 16 , -R 15 -N(R 14 )C(O)R 16 , -R 15 -N(R 14 )S(O) t R 16 (t is 1 or 2), -R 15 -S(O) t OR 16 (t is 1 or 2), -R 15 -S(O) p R 16 (p is 0, 1, or 2) and -R 15 -S(O) t N(R 14t is 1 or 2; and each R 14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 15 is independently a direct bond or a linear or branched alkylene or alkenylene chain, and each R 16 is independently alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, or heteroaryl.

[0037] "Fused" refers to any ring system described herein that is fused to an existing ring structure of a compound of the present invention. When the fused ring system is a heterocyclyl or heteroaryl, any carbon atom on the existing ring structure that becomes part of the fused ring system can be replaced with a nitrogen atom.

[0038] "Halo" refers to the following halogen substituents: bromo, chloro, fluoro, and iodo.

[0039] "Haloalkyl" refers to an alkyl radical further substituted by one or more halogen substituents as defined above. The number of halo substituents contained in the haloalkyl is from 1 to the total number of hydrogen atoms available for replacement with halo substituents (e.g., perfluoroalkyl). Non-limiting examples of haloalkyl include trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, and the like. For optionally substituted haloalkyl, the hydrogen atoms attached to the carbon atoms of the alkyl portion of the haloalkyl radical can be optionally replaced with substituents as defined above for optionally substituted alkyl.

[0040] "Haloalkenyl" refers to an alkenyl radical further substituted with one or more halo substituents as defined above. The number of halo substituents contained in a haloalkenyl is from 1 to the total number of hydrogen atoms available for replacement with halo substituents (e.g., perfluoroalkenyl). Non-limiting examples of haloalkenyl include 2,2-difluoroethenyl, 3-chloroprop-1-enyl, and the like. For optionally substituted haloalkenyls, the hydrogen atoms attached to the carbon atoms of the alkenyl portion of the haloalkenyl radical can be optionally replaced with substituents as defined above for optionally substituted alkenyl groups.

[0041] "Haloalkynyl" refers to an alkynyl radical further substituted with one or more halo substituents as defined above. The number of halo substituents contained in a haloalkynyl is from 1 and up to the total number of hydrogen atoms available for replacement with the halo substituents (e.g., perfluoroalkynyl). Non-limiting examples of haloalkynyl include 3-chloroprop-1-ynyl and the like. The alkynyl portion of the haloalkynyl radical can be additionally optionally substituted as defined above for an alkynyl group.

[0042] "Heteroarylalkyl" refers to a group of the formula -R a -R b where R a is alkylene, and R b is heteroaryl. The alkylene and heteroaryl portions of an optionally substituted heteroarylalkyl are optionally substituted as described herein for alkylene and heteroaryl, respectively.

[0043] "Heterocyclyl" refers to a stable 3- to 18-membered non-aromatic ring system radical having 2-12 carbons and a total of 1-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur. Heterocyclyl radicals are monocyclic, bicyclic, tricyclic, or tetracyclic ring systems. Bicyclic, tricyclic, or tetracyclic heterocyclyls are fused, spiro, and / or bridged ring systems. Heterocyclyl radicals can be saturated or unsaturated. Unsaturated heterocyclyls contain one, two, or three carbon-carbon double bonds and / or one carbon-carbon triple bond. Optionally substituted heterocyclyls include alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, aryl, aralkyl, cycloalkyl, heterocyclyl, heteroaryl, -R 15 -OR 14 , -R 15 -OC(O)-R 14 , -R 15 -N(R 14 )2, -R 15 -C(O)R 14 , -R 15 -C(O)OR 14 , -R 15 -C(O)N(R 14 )2, -R 15 -N(R 14 )C(O)OR 16 , -R 15 -N(R 14 )C(O)R 16 , -R 15 -N(R 14 )S(O) t R 16 (t is 1 or 2), -R 15 -S(O) t OR 16 (t is 1 or 2), -R 15 -S(O) p R 16 (p is 0, 1, or 2) and -R 15 -S(O) t N(R 14t is 1 or 2; and each R 14 is independently hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 15 is independently a direct bond or a linear or branched alkylene or alkenylene chain, and each R 16 is independently alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl. The nitrogen, carbon, or sulfur atom in a heterocyclyl radical can be optionally oxidized (when the substituent is oxo and on the heteroatom), and the nitrogen atom can be optionally quaternized (when the substituent is alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclyl, heteroaryl, -R 15 -OR 14 , -R 15 -OC(O)-R 14 , -R 15 -N(R 14 )2, -R 15 -C(O)R 14 , -R 15 -C(O)OR 14 , -R 15 -C(O)N(R 14 )2, -R 15 -N(R 14 )C(O)OR 16 , -R 15 -N(R 14 )C(O)R 16 , -R 15 -N(R 14 )S(O) t R 16 (t is 1 or 2), -R 15 -S(O) t OR 16 (t is 1 or 2), -R 15 -S(O) p R 16 (p is 0, 1, or 2), and -R 15 -S(O) t N(R 14)2 (t is 1 or 2), and R 15 is a linear or branched alkylene or alkenylene chain, R 14 and R 16 is as defined above. Examples of optionally substituted heterocyclyl radicals include, but are not limited to, azetidinyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl.

[0044] "Heterocyclylene" refers to a heterocyclyl in which a hydrogen atom is replaced at a valence. An optionally substituted heterocyclylene is optionally substituted as described herein for heterocyclyl.

[0045] "Heteroaryl" refers to a 5-18 membered ring system radical containing at least one aromatic ring, having a carbon number of 1-17 carbon atoms, and containing a total of 1-10 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. Heteroaryl radicals are monocyclic, bicyclic, tricyclic, or tetracyclic ring systems. Bicyclic, tricyclic, or tetracyclic heteroaryl radicals are fused and / or bridged ring systems. Optionally substituted heteroaryl can be alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, oxo, aryl, aralkyl, cycloalkyl, heterocyclyl, heteroaryl, or heteroarylalkyl, -R 15 -OR 14 , -R 15 -OC(O)-R 14 , -R 15 -N(R14 )2, -R 15 -C(O)R 14 , -R 15 -C(O)OR 14 , -R 15 -C(O)N(R 14 )2, -R 15 -N(R 14 )C(O)OR 16 , -R 15 -N(R 14 )C(O)R 16 , -R 15 -N(R 14 )S(O) t R 16 (t is 1 or 2), -R 15 -S(O) t OR 16 (t is 1 or 2), -R 15 -S(O) t R 16 (p is 0, 1, or 2) and -R 15 -S(O) t N(R 14 t is 1 or 2; and each R 14 is independently hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each R 15 is independently a direct bond or a linear or branched alkylene or alkenylene chain, and each R 16 is alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl. The nitrogen, carbon, or sulfur atoms in a heterocyclyl radical may be optionally oxidized (when the substituent is oxo and present on the heteroatom), provided that at least one ring in the heteroaryl remains aromatic, and the nitrogen atom may be optionally quaternized (when the substituent is alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclyl, heteroaryl, -R 15 -OR 14 , -R15 -OC(O)-R 14 , -R 15 -N(R 14 )2, -R 15 -C(O)R 14 , -R 15 -C(O)OR 14 , -R 15 -C(O)N(R 14 )2, -R 15 -N(R 14 )C(O)OR 16 , -R 15 -N(R 14 )C(O)R 16 , -R 15 -N(R 14 )S(O) t R 16 (t is 1 or 2), -R 15 -S(O) t OR 16 (t is 1 or 2), -R 15 -S(O) p R 16 (p is 0, 1, or 2), and -R 15 -S(O) t N(R 14 )2 (t is 1 or 2), and R 15 is a linear or branched alkylene or alkenylene chain, R 14 and R 16is as defined above. Examples of optionally substituted heteroaryl radicals are azepinyl, acridinyl, benzimidazolyl, benzthiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, These include, but are not limited to, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl).

[0046] The invention disclosed herein is also meant to encompass all pharma- ceutically acceptable compounds of formula (I) that are isotopically labeled with one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that may be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, e.g., 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N,15 O. 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I. These radiolabeled compounds may be useful, for example, to help determine or measure the effectiveness of compounds by characterizing the site or mode of action on ATM and DNA-PK enzymes, or the binding affinity to pharmacologically important sites of action on ATM and DNA-PK enzymes. Certain isotopically labeled compounds of formula (I), for example those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotope tritium, i.e. 3 H and carbon-14, i.e. 14 C are particularly useful for this purpose given their ease of incorporation and ready means of detection.

[0047] Deuterium, i.e. 2 Substitution with heavier isotopes, such as H, may confer certain therapeutic advantages resulting from greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in some circumstances.

[0048] 11 C. 18 F, 15 O and 13 Substitution with positron emitting isotopes, such as N, can be useful in positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art, or by processes analogous to those described in the Examples and Preparations described below, substituting an appropriate isotopically labeled reagent for the unlabeled reagent previously used.

[0049] The invention disclosed herein is also meant to encompass in vivo metabolic products of the disclosed compounds. Such products can result, for example, from oxidation, reduction, hydrolysis, amidation, esterification, etc., of the administered compound, primarily by enzymatic processes. Thus, the invention includes compounds produced by a process comprising contacting a compound of the invention with a mammal for a period of time sufficient to produce its metabolic products. Such products are typically identified by administering a detectable dose of a radiolabeled compound of the invention to an animal, such as a rat, mouse, guinea pig, dog, monkey, or human, allowing sufficient time for metabolism to occur, and isolating the conversion products from urine, blood, or other biological samples.

[0050] "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

[0051] "Mammal" includes both humans and domestic animals, such as laboratory animals and household pets (eg, cats, dogs, pigs, cows, sheep, goats, horses, rabbits), as well as non-domestic animals, such as wild animals.

[0052] "Optional" or "optionally" means that the subsequently described circumstance event may or may not occur, and that the description includes cases where the event or circumstance occurs and cases where it does not occur. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted, and that the description includes both substituted aryl radicals and aryl radicals that have no substitution.

[0053] By "patient" is meant a human or non-human animal (e.g., a mammal) suffering from a disease or condition, as determined by a qualified professional (e.g., a physician, nurse, or veterinarian), whether or not known upon test(s) in the art of a sample(s) from the patient.

[0054] A "pharmaceutically acceptable carrier, diluent, or excipient" includes, without limitation, any adjuvant, carrier, excipient, lubricant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonicity agent, solvent, or emulsifier approved by the U.S. Food and Drug Administration as acceptable for use in humans or veterinary medicine.

[0055] "Pharmaceutically acceptable salts" as used herein refer to salts that are suitable for use in contact with human and animal tissues without undue toxicity, irritation, allergic reactions, etc., within the scope of sound medical judgment, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and Pharmaceutical Salts: Properties, Selection, and Use (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. Pharmaceutically acceptable salts include acid addition salts and base addition salts.

[0056] "Pharmaceutically acceptable acid addition salts" refer to those acids which retain the biological effectiveness and properties of the free base, which are not biologically or otherwise undesirable, and include, for example, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptan acid, squalene ... The term "salicylic acid" refers to those salts formed with organic acids such as carboxylic acid, carboxylic acid, glycerol acid, carboxylic acid, tert-butyl ...

[0057] "Pharmaceutically acceptable base addition salts" refer to those salts which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable. These salts are prepared from the addition of an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

[0058] In many cases, crystallization produces a solvate of the compound of the present invention. As used herein, the term "solvate" refers to an aggregate that contains one or more molecules of the compound of the present invention together with one or more solvent molecules. The solvent can be water, in which case the solvate can be a hydrate. Alternatively, the solvent can be an organic solvent. Thus, the compound of the present invention can exist as a hydrate, including monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate, etc., as well as the corresponding solvate forms. The compound of the present invention can be a true solvate, while in other cases, the compound of the present invention can simply retain adventitious water or be a mixture of water and some adventitious solvent.

[0059] A "pharmaceutical composition" refers to a vehicle generally accepted in the art for the formulation of a compound of the invention and the delivery of a biologically active compound to a mammal, e.g., a human. Such a vehicle includes any pharma- ceutically acceptable carrier, diluent, or excipient therefor.

[0060] "Therapeutically effective amount" refers to an amount of a compound of the present invention that, when administered to a mammal, preferably a human, is sufficient to effect treatment, as defined below, in the mammal, preferably a human or a dog. The amount of a compound of the present invention, or another pharmaceutical agent (e.g., an antitumor agent), that constitutes a "therapeutically effective amount" varies depending on the compound, the condition and its severity, the mode of administration, and the age of the mammal being treated, but can be routinely determined by one of ordinary skill in the art having regard to his own knowledge and this disclosure.

[0061] As used herein, "treating" or "treatment" extends to the treatment of a disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest; (i) preventing a disease or condition from occurring in a mammal, particularly where such mammal is predisposed to the condition but has not yet been diagnosed as having it; (ii) inhibiting a disease or condition, i.e., preventing its onset; (iii) alleviating the disease or condition, i.e., causing the regression of the disease or condition; or (iv) Relieving symptoms resulting from a disease or condition, including relieving pain without addressing the underlying disease or condition. As used herein, the terms "disease" and "condition" may be used interchangeably or may differ in that a particular ailment or condition may not have a known causative agent (so the etiology has not yet been elucidated) and thus it is not yet recognized as a disease, but only as an undesirable state or syndrome, and a particular set of symptoms has been more or less identified by the clinician.

[0062] The compounds of the present invention, or their pharma- ceutically acceptable salts, may contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optionally pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as chromatography and fractional recrystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors, or resolution of the racemates (or racemates of salts or derivatives), using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, the compounds are intended to include both E and Z geometric isomers, as well as all tautomeric forms.

[0063] "Stereoisomers" refer to compounds consisting of the same atoms joined by the same bonds, but with different, incompatible three-dimensional structures. The present invention contemplates various stereoisomers and mixtures thereof, and includes "enantiomers," which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.

[0064] "Tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present invention includes tautomers of any such compounds.

[0065] Also within the scope of the present invention are the intermediate compounds of formula (I), as well as all polymorphs of the aforementioned species and their crystal habits. [Brief description of the drawings]

[0066] [Figure 1] 1 is an image of an immunoblot from a representative experiment evaluating the effect of compound 569 on MCF7 cells with or without radiation. [Diagram 2] 1 is a graph showing the results of a clonogenic survival assay examining MCF7 cell viability following exposure to vehicle (DMSO) or compound 569, with or without radiation. [Diagram 3] 3 is an image of an immunoblot showing induction of phosphorylation of TBK1 by compound 569, a selective ATM inhibitor (ATMi), a selective DNA-PK inhibitor (DNA-PKi), and a combination of a selective ATM inhibitor and a selective DNA-PK inhibitor (Ai+Di) in HCT116 cells expressing wild-type p53 or negative for p53 expression. In FIG. 3, p.ATM, p.DNA-PK, p.TBK1, and p.STING represent the phosphorylated forms of ATM, DNA-PK, TBK1, and STING, respectively. [Figure 4] 4 is an immunoblot showing inhibition of radiation-induced autophosphorylation of DNA-PK kinase and radiation-induced phosphorylation of the ATM substrate, KAP1, by compound 569 in FADU head and neck squamous cell carcinoma (HNSCC) human tumor xenografts. In FIG. 4, pDNA-PK and pKAP1 represent the phosphorylated forms of DNA-PK and KAP1, respectively. [Diagram 5] 5 is an immunoblot showing the inhibition of radiation-induced autophosphorylation of DNA-PK kinase and radiation-induced phosphorylation of the ATM substrate, KAP1, by compound 569 in MDA-MB-231 breast cancer human tumor xenografts. In FIG. 5, pDNA-PK and pKAP1 represent the phosphorylated forms of DNA-PK and KAP1, respectively. [Figure 6] FIG. 6 shows dosing of a FADU subcutaneous human xenograft mouse model with Compound 569 and / or IR, qd×3. The median relative tumor volume over time for each group in the study is shown. In FIG. 6, "569" refers to Compound 569, "Veh" refers to vehicle, and "Rad" refers to radiation. [Figure 7]Figure 7 depicts Kaplan-Meier 5-fold survival for each group administered Compound 569 and / or IR, qdx3, to the FADU subcutaneous human xenograft mouse model. In Figure 7, "569" means Compound 569, "Veh" means vehicle, and "Rad" means radiation. [Figure 8] FIG. 8 shows dosing of a MDA-MB-231 subcutaneous human xenograft mouse model with Compound 569 and / or IR, qd×3. The median relative tumor volume over time for each group in the study is shown. In FIG. 8, "569" refers to Compound 569, "Veh" refers to vehicle, and "Rad" refers to radiation. [Figure 9] 9 depicts Kaplan-Meier 5-fold survival data for each group administered Compound 569 and / or IR, qd×3, to the MDA-MB-231 subcutaneous human xenograft mouse model. In FIG. 9, "569" refers to Compound 569, "Veh" refers to vehicle, and "Rad" refers to radiation.

[0067] Compounds, Compositions, and Methods The present invention provides compounds and compositions that may be useful, for example, alone or in combination with radiation therapy and / or anti-tumor therapy, in the treatment of neoplastic diseases (e.g., cancer, e.g., cancers described herein). The compounds are compounds of formula (I):

[0068] [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, Z is CH, CR 3 , or N, Y is CHR 5 or NR 6 and n is 0, 1, 2, or 3; R 1 But -OLN(R 7 ) 2 or optionally substituted 4-membered saturated N-heterocyclyl; R2 is C1-3 alkyl; Each R 3 are independently halogen or optionally substituted C 1-3 is alkyl, R 4 is optionally substituted alkyl; R 5 is hydrogen, optionally substituted C 1-3 alkyl, or benzyloxy; R 6 is arbitrarily replaced by C 1-3 is alkyl, Each R 7 are independently H or optionally substituted C 1-3 is alkyl, The compound may be of formula (I), or a pharma- ceutically acceptable salt thereof, wherein L is optionally substituted ethylene.

[0069] Advantageously, the compounds of the invention (e.g., compounds 568, 569, or 570) may exhibit superior inhibitory activity against ATM and DNA-PK. Advantageously, the compounds of the invention (e.g., compounds 568, 569, or 570) may exhibit superior selectivity as measured by reducing off-target activity (e.g., mTOR inhibition, PI3K α / δ inhibition, and / or hERG inhibition). For example, the compounds of the invention (e.g., compounds 568, 569, or 570) may exhibit superior selectivity as measured by reducing off-target activity (e.g., mTOR inhibition, PI3K α / δ inhibition, and / or hERG inhibition) compared to ATM IC 50 or DNA-PK IC 50 at least 10-fold (e.g., at least 20-fold) greater than mTOR IC 50 The compounds of the invention (e.g., compounds 568, 569, or 570) may have an mTOR IC of 10 nM or more (e.g., >100 nM). 50 Additionally or alternatively, a compound of the invention (e.g., Compound 568, 569, or 570) may have an ATM IC 50 or DNA-PK IC 50 hERG IC50 The compounds of the invention (e.g., compounds 568, 569, or 570) may have a hERG IC of 3 μM or greater (e.g., 10 μM or greater). 50 may have:

[0070] Advantageously, the compounds of the present invention (e.g., compounds 568, 569, or 570) have excellent pharmacokinetic properties (e.g., C max , AUC, and / or t 1 / 2 ) can be shown.

[0071] In some embodiments, the compound is selected from the group consisting of:

[0072] [Table 1]

[0073] The compounds of the present invention are advantageous in that they can inhibit ATM (ataxia telangiectasia mutated) and DNA-PK kinase. In particular, ATM (ataxia telangiectasia mutated) and DNA-PK kinase are key regulators of cellular response to DNA breaks, and inhibition of either of these molecules significantly increases the sensitivity of cells to ionizing radiation. Thus, the compounds of the present invention can be effective inhibitors of the action of ATM and DNA-PK, with or without radiation, and with or without chemotherapy or immunotherapy, to provide effective treatment for the treatment of neoplastic diseases (e.g., cancer, such as those cancers described herein). Treatment of patients with the compounds of the present invention can delay or eliminate the repair of DNA damage caused by radiation therapy. As a result, patients receiving the compounds of the present invention can show a better response to antitumor therapy. Advantageously, patients receiving the compounds of the present invention can derive therapeutic benefit by increasing tumor control from standard doses of radiation therapy, or by achieving similar levels of tumor control from lower doses of ionizing radiation than are typically used in patients not receiving the compounds of the present invention. Advantageously, lower doses of ionizing radiation may cause less damage to non-cancerous tissue than doses required in patients not receiving the compounds of the invention.

[0074] Humans and mice carrying loss-of-function mutations in the ATM or PRKDC genes, which code for ataxia telangiectasia mutated (ATM) kinase and DNA-dependent protein kinase (DNA-PK), respectively, are hypersensitive to ionizing radiation. Inhibiting ATM kinase and DNA-PK kinase together can be effective in sensitizing tumor cells to radiation or DNA-damaging agents (e.g., antitumor agents). The efficacy of dual inhibition of ATM and DNA-PK kinases can be superior to inhibition of either kinase.

[0075] In addition, compounds of the invention may advantageously exhibit reduced inhibition of other kinases (ATR and mTOR) and therefore may exhibit reduced toxicity.

[0076] The compounds of the invention may sensitize tumor cells to radiation and / or antitumor agents.

[0077] method In another aspect, the present invention provides a method for the treatment of a neoplastic disease (e.g., cancer) in a mammal, preferably a human or a dog, comprising administering a therapeutically effective amount of a compound of the present invention to a mammal in need thereof. In some embodiments, the compound is administered to a mammal undergoing radiation therapy.

[0078] In another aspect, the present invention provides a method for treating a neoplastic disease (e.g., cancer) in a mammal, the method comprising administering a therapeutically effective amount of a compound of the present invention to a mammal in need thereof. In some embodiments, the compound is administered to the mammal in combination with a DNA damaging agent. Non-limiting examples of DNA damaging agents include cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, calicheamicin, and PARP inhibitors.

[0079] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharma- ceutical acceptable excipient. In one embodiment, the pharmaceutical composition comprises a compound of the present invention in a pharma- ceutical acceptable carrier in an amount effective to treat a neoplastic disease in an animal, preferably a mammal.

[0080] When the compound of the present invention is used in combination therapy, it can increase the efficacy of other radiation therapy or drug therapy, if the dose of other treatment can be reduced, and this can reduce the frequency and / or severity of adverse events related to other drug therapy.For example, the side effects of radiation (e.g., oral or gastrointestinal mucositis, dermatitis, interstitial pneumonia, or fatigue) can be reduced in patients receiving combination therapy with the compound of the present invention and reduced dose of radiation therapy compared to patients receiving full dose of radiation therapy without the compound of the present invention (e.g., the incidence of adverse events can be reduced by at least 1%, 5%, 10%, or 20%).In addition, other adverse events that can be reduced in patients receiving combination therapy with the compound of the present invention and reduced dose of radiation therapy compared to patients receiving full dose of radiation therapy without the compound of the present invention (e.g., the incidence of adverse events can be reduced by at least 1%, 5%, 10%, or 20%) can be late effects of radiation, such as radiation-induced pulmonary fibrosis, cardiac damage, intestinal obstruction, nerve damage, vascular damage, lymphedema, brain necrosis, or radiation-induced cancer. Similarly, when the compound is administered in combination with another anticancer drug (e.g., as described herein), the combination can cause the same or even increased tumor cell death even if the dose of the other anticancer drug is reduced.Thus, reducing the dose of the other anticancer drug can reduce the severity of the adverse events caused by the other anticancer drug.

[0081] In another aspect, the present invention relates to the use of the compounds of the present invention as stereoisomers, enantiomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, as described above, or the use of pharmaceutical compositions comprising pharmaceutically acceptable excipients and compounds of the present invention as stereoisomers, enantiomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, as described above, in the preparation of medicaments for use in the treatment of disease.In some embodiments, the compounds of the present invention are administered in combination with radiation therapy.In other embodiments, the compounds of the present invention are administered in combination with DNA damaging agents. In further embodiments, the compounds of the present invention are administered in combination with an antitumor immunotherapeutic agent (e.g., ipilimumab, ofatumumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, obinutuzumab, ocaratuzumab, tremelimumab, spartalizumab, camrelizumab, sintilimab, tislelizumab, toripalimab, dostarlimab, veltuzumab, INCMGA00012, AMP-224, AMP-514, KN035, CK-301, AUNP12, CA-170, or BMS-986189). In other embodiments, the antitumor immunotherapeutic agent is ofatumumab, obinutuzumab, ocaratuzumab, or veltuzumab. In yet other embodiments, the antitumor immunotherapeutic agent is nivolumab, pembrolizumab, cemiplimab, spartalizumab, camrelizumab, sintilimab, tislelizumab, toripalimab, dostarlimab, INCMGA00012, AMP-224, or AMP-514. In yet other embodiments, the antitumor immunotherapeutic agent is atezolizumab, avelumab, durvalumab, KN035, CK-301, AUNP12, CA-170, or BMS-986189. In certain preferred combination therapy embodiments, the compounds of the present invention are administered in combination with an antitumor immunotherapeutic agent.

[0082] The method of the present invention can be used to treat neoplastic disease as described herein.Neoplastic disease can be, for example, pre-malignant or malignant tumor (e.g., solid or liquid tumor).Malignant tumor is typically called cancer.In certain embodiments, neoplastic disease is cancer.

[0083] In further embodiments, examples of cancers that may be treated using the methods and uses disclosed herein include, but are not limited to, hematological cancers, such as leukemia and lymphoma.Non-limiting examples of cancers include acute myeloid leukemia, acute lymphoblastic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, lymphoblastic T-cell leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, hairy cell leukemia, chronic neutrophilic leukemia, plasmacytoma, immunoblastic large cell leukemia, mantle cell leukemia, multiple myeloma, malignant lymphoma, diffuse large B-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, lymphoblastic T-cell lymphoma, Burkitt's lymphoma, and follicular lymphoma.

[0084] In yet another embodiment, examples of cancers that may be treated using the methods and uses disclosed herein include, but are not limited to, solid tumors.Non-limiting examples of solid tumors include brain tumors (e.g., astrocytoma, glioma, glioblastoma, medulloblastoma, or ependymoma), bladder cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gastrointestinal stromal tumor, gastric cancer, head and neck cancer, buccal cancer, oral cancer, hepatocellular carcinoma, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, nasopharyngeal carcinoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, salivary gland cancer, sarcoma, testicular cancer, urothelial carcinoma, vulvar cancer, and Wilms' tumor. Preferably, the methods of the invention are used in the treatment of lung cancer, head and neck cancer, pancreatic cancer, rectal cancer, glioblastoma, hepatocellular carcinoma, cholangiocarcinoma, metastatic liver lesions, melanoma, osteosarcoma, soft tissue sarcoma, endometrial cancer, cervical cancer, prostate cancer, or Merkel cell carcinoma.

[0085] In further embodiments, examples of cancers that may be treated using the methods and uses disclosed herein are not limited to metastases and metastatic cancers. For example, the methods and uses disclosed herein for treating cancer may include treatment of both primary tumors and metastases.

[0086] In some embodiments, the method of the present invention can reduce tumor size in a subject by, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or eliminate tumor (e.g., compared to tumor size at the start of therapy, or compared to a reference subject receiving a placebo instead of a compound of the present invention). In some embodiments, the method of the present invention can reduce tumor burden in a subject by, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or eliminate tumor (e.g., compared to tumor burden at the start of therapy, or compared to a reference subject receiving a placebo instead of a compound of the present invention). In some embodiments, the methods of the present invention can increase the average survival time of a subject by, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, or 200% (e.g., compared to a reference subject receiving a placebo instead of a compound of the present invention). In some embodiments, the methods of the present invention can increase the ability of radiation therapy or drug therapy to relieve pain or other symptoms for a longer average period of time for a subject by, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, or 200% (e.g., compared to a reference subject receiving a placebo instead of a compound of the present invention).

[0087] In some embodiments, the methods and uses disclosed herein include pre-treatment of a patient with a dual ATM and DNA-PK inhibitor prior to administration of radiation therapy or a DNA damaging agent. Pre-treatment of a patient with a dual ATM and DNA-PK inhibitor can delay or eliminate repair of DNA damage following radiation therapy.

[0088] Radiation therapy uses X-rays (photons), 60 Radiation therapy includes, but is not limited to, external beam radiation therapy with gamma rays from cobalt or other radioisotopes, neutrons, electrons, protons, carbon ions, helium ions, and other charged particles. Radiation therapy includes brachytherapy and external beam radiation therapy with gamma rays, alpha particles, beta particles, Auger electrons, or 32 Phosphorescence, 67 copper, 77 Bromin, 89 strontium, 90 yttrium, 105 rhodium, 131 Iodine, 137 cesium, 149 Prometheum, 153 samarium, 166 holmium, 177 lutetium, 186 rhenium, 188 rhenium, 199 gold, 211 Astatine, 213 Bismuth, 223 radium, 225 Actinium, or 227 Thorium, 192 iridium, 67 gallium, 103 palladium, 125 Iodine and other radioisotopes (e.g. 192 iridium, 125 Iodine, 137 cesium, 103 palladium, 32 Phosphorescence, 90 yttrium, 67 gallium, 211 Astatine, or 223 Radiation therapy also includes radiopharmaceuticals that emit other types of radioactive particles from isotopes, including radium. 131 Iodine, 90 yttrium, 225 Actinium, 211 Astatine, 67 gallium, 177 lutetium, 227Also included is radioimmunotherapy (RIT) using antibodies or small molecules conjugated to radioisotopes, including thorium, and other radioisotopes.

[0089] In some embodiments, the combination therapy includes administration to the patient of ATM and DNA-PK inhibitors and anti-tumor agents, such as cisplatin, oxaliplatin, carboplatin, topoisomerase I inhibitors, topoisomerase II inhibitors, anthracyclines, valrubicin, idarubicin, calicheamicin, PARP inhibitors (e.g., olaparib, rucaparib, niraparib, veliparib, or talazoparib), as well as other anti-cancer agents known to those of skill in the art.

[0090] In certain embodiments, the combination therapy includes administration to the patient of an ATM and DNA-PK inhibitor and an anti-tumor immunotherapeutic agent, including, but not limited to, ipilimumab, ofatumumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, and the like.

[0091] In the combination therapies described herein, the ATM and DNA-PK inhibitors may be administered to a subject simultaneously or sequentially (eg, before or after) the other drug.

[0092] Preparation of the Compounds of the Invention The compounds of the present invention can be prepared using methods and techniques known in the art.Suitable processes for synthesizing these compounds are provided in the examples.In general, compounds of formula (I) can be prepared according to the schemes described below.The sources of starting materials for these reactions are also described.

[0093] Protective groups can be added or removed in the preparation of the compounds of the invention according to standard techniques known to those skilled in the art and described herein. The use of protecting groups is described in detail in Greene, TW and PGM Huts, Greene's Protective Groups in Organic Synthesis (2006), 4 thEd., Wiley. The protecting group can also be a polymeric resin, such as Wang resin or 2-chlorotrityl chloride resin.

[0094] It will be appreciated by those skilled in the art that such protected derivatives of the compounds of the invention may not have pharmacological activity in themselves, but they can be administered to a mammal and then metabolized in the body to form a pharmacologically active compound of the invention.

[0095] All of the compounds described below as prepared and which may exist in free base or acid form can be converted to their pharma- ceutically acceptable salts by treatment with an appropriate inorganic or organic base or acid. The salts of the compounds prepared below can be converted to their free base or acid form by standard techniques. It is understood that all polymorphs, amorphous forms, anhydrates, hydrates, solvates and salts of the compounds of the present invention are intended to be within the scope of the present invention. Furthermore, all compounds of the present invention that contain acid or ester groups can be converted to the corresponding ester or acid, respectively, by methods known to those skilled in the art or by methods described herein.

[0096] A general representation of the preparation of many of these compounds is shown in Scheme 1 below. The compounds are prepared by coupling of various components of the molecule: Suzuki coupling of halo-substituted compound 3 (or 2') with boronic acid or borate compound 2 (3'). Further reactions may or may not be required to provide the synthesis of the compounds of the invention. The preparation of certain compounds of the invention is shown in the following schemes.

[0097] [ka] In the aryl-aryl coupling reaction, the halogen can be iodo, bromo, or chloro, preferably bromo or iodo. In this method, the halogen substitution can be converted to an aryl substitution using Suzuki coupling reaction conditions. The conditions of this method are disclosed in many publications reviewed by A. Suzuki in the article entitled "The Suzuki reaction with arylboron compounds in arene chemistry" in Modern Arene Chemistry 2002,53-106. In carrying out this reaction, any of the conventional suitable conditions in Suzuki reactions can be utilized. In general, the Suzuki coupling reaction is carried out in the presence of a transition metal catalyst such as a palladium catalyst utilizing any conventional organic solvent and a weak inorganic or organic base for this reaction. Among the preferred organic solvents are polar aprotic solvents. In preparing the compounds of the present invention, any conventional polar aprotic solvent can be utilized. The suitable solvents are conventional, particularly high boiling solvents such as dimethoxyethane. The weak inorganic base can be a carbonate or bicarbonate, such as potassium carbonate or cesium carbonate. The organic base can be an amine, such as triethylamine.

[0098] [ka] Specifically, other spirooxindole intermediates 7 are synthesized as shown in Scheme 2. Cyclyl or heterocyclyl substituted esters 5 are treated with a strong base, such as, but not limited to, lithium diisopropylamide, in an anhydrous solvent, such as, but not limited to, tetrahydrofuran, at low temperature to react with starting material 4, either commercially available or prepared by one skilled in the art following literature describing methods to provide intermediates 6. Intermediate 6 is reduced with a reducing agent, such as, but not limited to, iron, to give the corresponding amino intermediate, which cyclizes to provide oxindole compound 7 in situ. Thus, compound 7 is then N-alkylated with an alkylating agent in a polar solvent, such as, but not limited to, N,N-dimethylformamide or tetrahydrofuran, in the presence of a base, such as, but not limited to, potassium carbonate or sodium hydride, thereby generating spirooxindole intermediate 8.

[0099] [ka] Specifically, the compound of formula (I) of the present invention can be synthesized as shown in Scheme 3. Commercially available 5-bromo-2-chloro-3-nitro-pyridine (9) reacts with nucleophile XH (10) in the presence of a strong base, such as, but not limited to, sodium hydride, to provide intermediate 11. Under palladium catalyzed conditions, borate 12 can be prepared and then reacted with spiro intermediate 8 to provide cross-coupling product 13. The nitro group in compound 13 is reduced to an amino group using a reducing agent, such as, but not limited to, iron, to provide intermediate 14. Reaction of 14 with different sulfonyl chlorides (15) provides the synthesis of compounds of formula (I).

[0100] [ka] Specifically, the compounds of formula (I) of the present invention can also be synthesized as shown in Scheme 4. The nitro group in compound 11 is reduced to an amino group using a reducing agent, such as, but not limited to, iron, to provide intermediate 16. Reaction of 16 with different sulfonyl chlorides (15) provides sulfonamide intermediates 17, which are converted to the corresponding borate 18 under palladium catalysis. Borate 18 can be coupled with halo compound 8 under Suzuki reaction conditions to provide compounds of formula (I).

[0101] In Scheme 3 and Scheme 4, cross-coupled compounds can also be synthesized using Suzuki coupling chemistry with components that reverse the halogen and boronate / boronic acid substitution patterns, for example, as shown in Scheme 5.

[0102] [ka] Specifically, the compound of formula (I) of the present invention can also be synthesized as shown in Scheme 5. Halo compound 8 can be converted to its corresponding borate 19 under palladium catalysis. Borate 19 can be coupled with halo compound 17 under Suzuki reaction conditions to provide the compound of formula (I).

[0103] In carrying out the method of the present invention, an effective amount of any one of the compounds of the present invention or any combination of the compounds of the present invention or their pharma- ceutically acceptable salts, either alone or in combination, is administered via any of the usual acceptable methods known in the art. Thus, the compounds or compositions can be administered orally (e.g., buccal), sublingually, parenterally (e.g., intramuscularly, intravenously, or subcutaneously), rectally (e.g., by suppository or lavage), transdermally (e.g., skin electroporation), or by inhalation (e.g., by aerosol), in the form of solid, liquid, or gaseous dosages, including tablets and suspensions. Administration can be in a single unit dosage form with continuous therapy, or in a free single dose therapy. The therapeutic composition can also be in the form of an oil emulsion or dispersion combined with a lipophilic salt such as pamoic acid, or in the form of a biodegradable sustained release composition for subcutaneous or intramuscular administration.

[0104] Pharmaceutical carriers useful for preparing the composition can be solid, liquid, or gaseous. Thus, the composition can take the form of tablets, pills, capsules, suppositories, powders, enteric coated or other protected preparations (e.g., bound to ion exchange resins or packaged in lipid-protein vesicles), sustained release preparations, solutions, suspensions, elixirs, aerosols, and the like. Carriers can be selected from a variety of oils, including those of petroleum, animal, vegetable, or synthetic origin, such as, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly for injectable solutions (when isotonic with blood). For example, formulations for intravenous administration include sterile aqueous solutions of the active ingredient(s) prepared by dissolving the solid active ingredient(s) in water to produce an aqueous solution and sterilizing the solution. Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, gelatin, malt, rice, flour, chalk, silica, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, etc. The composition may be subjected to conventional pharmaceutical additives such as preservatives, stabilizers, wetting agents or emulsifiers, salts for adjusting osmotic pressure, buffers, etc. Suitable pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences by EW Martin. Such compositions will in any event contain an effective amount of active compound together with a suitable carrier to prepare the appropriate dosage form for proper administration to the recipient.

[0105] The dosage of the compounds of the present invention will depend on many factors, such as the mode of administration, the age and weight of the patient, and the condition of the patient being treated, and will ultimately be determined by the attending physician or veterinarian. Such an amount of active compound determined by the attending physician or veterinarian is referred to herein and in the claims as an "effective amount."

[0106] The present invention will now be further described in the following examples, which are intended as illustrations only and not as limiting the scope of the invention. EXAMPLES

[0107] Reagents were purchased from Aldrich, Sigma, TCI (Shanghai) Development, Chembon Pharmaceutical Co., Ltd, Zhangjiagang Aimate Huaxue Youxiangongsi, Changzhou Qinuo BioTech Co. Ltd, and Shanghai Weiyuan Fine Fluorine Technology Development Co., Ltd, or other sources as listed below, and used without further purification. Reactions using microwave irradiation for heating were carried out using Biotage Initiator+. Purification to multi-milligram to multi-gram scale was carried out by methods known to those skilled in the art, such as silica gel flash column chromatography elution, which in some cases could also be effected by the use of disposable pre-packed silica gel columns (Welch / Agela) eluted with a Biotage CombiFlash® system.

[0108] For the purpose of determining compound identity and purity, an analytical LC-MS (liquid chromatography / mass spectrometry) system was used, typically consisting of a Waters ZQ™ platform with electrospray ionization in positive ion detection mode on an Agilent 1100 series HPLC equipped with an autosampler. The column was typically a Water Xterra MS C18, 3.0×50 mm, 5 μm. The flow rate was 1 mL / min and the injection volume was 10 μL. UV detection was in the range of 210-400 nm. The mobile phase consisted of solvent A (water plus 0.06% TFA) and solvent B (acetonitrile plus 0.05% TFA) with a gradient of 100% solvent A for 0.7 min, changed to 100% solvent B over 3.75 min, maintained for 1.1 min, then changed back to 100% solvent A for 0.2 min.

[0109] For some separations, the use of supercritical fluid chromatography may also be useful. Supercritical fluid chromatography separations were performed using a Mettler-Toledo Minigram system with the following typical conditions: 12 mm AD column eluted with 40% MeOH in 2.0 mL / min supercritical fluid CO2 at 100 bar, 30° C. In the case of analytes with basic amino groups, 0.2% isopropylamine was added to the methanol modifier.

[0110] Many compounds of formula (I) were also purified by reversed-phase HPLC using methods well known to those skilled in the art. In some cases, preparative HPLC purification was performed using a PE Sciex 150 EX Mass Spec controlling a Gilson 215 collector and a Leap autoinjector connected to a Shimadzu preparative HPLC system. Compounds were collected from the elution stream using MS detection in positive ion detection. Elution of compounds from a C-18 column (2.0×10 cm, eluted at 20 mL / min) was effected using a suitable linear gradient mode over 10 min of solvent (A) 0.05% TFA / H2O and solvent (B) 0.035% TFA / acetyl nitrile. For injection into the HPLC system, crude samples were dissolved in a mixture of methanol, acetyl nitrile, and DMSO.

[0111] Compounds were analyzed using either a Bruker ADVANCE III HD 400MHz spectrometer or a Bruker AVANCE 300MHz spectrometer. 1 It was characterized by H-NMR.

[0112] [Table 2]

[0113] Preparation of compounds

[0114] [ka] Methyl 1-(6-bromo-7-fluoro-3-nitroquinolin-4-yl)cyclobutane-1-carboxylate: A solution of methyl cyclobutanecarboxylate (0.73 g, 6.38 mmol) in tetrahydrofuran (5.00 mL) was treated with freshly prepared lithium diisopropylamide (6.38 mmol) in tetrahydrofuran (45.0 mL) at −78° C. for 1 h under nitrogen atmosphere, followed by the addition of 6-bromo-4-chloro-7-fluoro-3-nitroquinoline (1.50 g, 4.91 mmol) in portions over 2 min. After stirring at ambient temperature for an additional hour, the reaction was quenched with saturated aqueous ammonium chloride solution (60.0 mL) and diluted with water (120 mL). The resulting mixture was extracted with ethyl acetate (3×60.0 mL). The combined organic layers were washed with brine (2×50.0 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with 1% to 2% ethyl acetate in petroleum ether to give the title compound as a colorless solid (240 mg, 13%): 1 H NMR(400MHz,CDCl3)δ9.14(s,1H),8.20(d,J=7.2Hz,1H),7.90(d,J=8.8Hz,1H),3.84(s,3H) ),3.12-2.99(m,1H),2.58-2.48(m,3H),1.91-1.83(m,1H),1.45-1.27(m,1H);MS:[(M+1)] + =383.17,385.17.

[0115] [ka] 8'-Bromo-7'-fluorospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one: A mixture of methyl 1-(6-bromo-7-fluoro-3-nitroquinolin-4-yl)cyclobutane-1-carboxylate (240 mg, 0.63 mmol) and iron powder (350 mg, 6.26 mmol) in acetic acid (10.0 mL) was stirred at ambient temperature for 18 hours. The resulting mixture was filtered and the filter cake was washed with ethyl acetate (5 x 100 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 1% to 2% methanol in dichloromethane to give the title compound as a pale yellow solid (100 mg, 50%): 1 H NMR(400MHz,DMSO-d6)δ10.75(s,1H),8.68(s,1H),8.52(d,J=7.5Hz,1H),7.98(d,J=10.1Hz,1H),2.90-2.75(m,2H),2.50-2.37(m,4H);MS:[(M+1)] + =321.15,323.15.

[0116] [ka] 8'-Bromo-7'-fluoro-3'-methylspiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one: A solution of 8-bromo-7-fluoro-2,3-dihydrospiro[cyclobutane-1,1-pyrrolo[2,3-c]quinolin]-2-one (100 mg, 0.31 mmol) in N,N-dimethylformamide (10.0 mL) was treated with sodium hydride (19.9 mg, 0.50 mmol, 60% dispersed in mineral oil) under nitrogen atmosphere for 30 min at 0° C., followed by the addition of iodomethane (66.3 mg, 0.47 mmol). After stirring at ambient temperature for an additional 40 min, the reaction was quenched with saturated aqueous ammonium chloride solution (10.0 mL). The resulting mixture was diluted with water (100 mL) and extracted with ethyl acetate (3×30.0 mL). The combined organic layers were washed with brine (2×20.0 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=20 / 1, v:v) to give the title compound as a colorless solid (102 mg, 98%): 1 H NMR(400MHz,CD3OD)δ8.78(s,1H),8.61(d,J=7.4Hz,1H),7.85(d,J=9.8Hz,1H),3 .36(s,3H),2.94-2.85(m,2H),2.72-2.61(m,3H),2.56-2.48(m,1H);MS:[(M+1)] + =335.00,337.00.

[0117] [ka] tert-Butyl N-(2-hydroxyethyl)-N-(propan-2-yl)carbamate: To a solution of 2-[(propan-2-yl)amino]ethan-1-ol (40.0 g, 388 mmol) in methanol (300 mL) was added di-tert-butyl dicarbonate (127 g, 586 mmol) dropwise at 0° C. The resulting mixture was stirred at ambient temperature for 2 h and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with 0% to 4% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless oil (65.0 g, 82%): 1 H NMR(400MHz, CDCl3)δ 4.17(s,1H),3.71(t,J=5.4Hz,2H),3.30(t,J=5.4Hz,2H),1.47(s,9H),1.12(d,J=6.8Hz,6H).

[0118] [ka] tert-Butyl N-[2-[(5-bromo-3-nitropyridin-2-yl)oxy]ethyl]-N-(propan-2-yl)carbamate: A solution of tert-butyl N-(2-hydroxyethyl)-N-(propan-2-yl)carbamate (15.4 g, 75.8 mmol) in anhydrous tetrahydrofuran (250 mL) was treated with sodium hydride (3.30 g, 82.1 mmol, 60% w / w dispersed in mineral oil) under nitrogen atmosphere at 0° C. for 1 h, and 5-bromo-2-chloro-3-nitropyridine (15.0 g, 63.2 mmol) was added over 2 min at 0° C. After an additional 2 h at 25° C., the reaction was quenched with saturated aqueous ammonium chloride solution (50.0 mL) and diluted with water (500 mL). The aqueous layer was extracted with ethyl acetate (3×150 mL). The combined organic layers were washed with brine (2×100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 1% to 18% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a pale yellow oil (18.0 g, 71%):1 H NMR(400MHz,CDCl3)δ 8.42(d,J=2.4Hz,1H),8.37(d,J=2.4Hz,1H),4.57(t,J=6.3Hz,2H),4.32(s ,1H),3.51(t,J=6.3Hz,2H),1.47(s,9H),1.15(d,J=6.9Hz,6H);MS:[(M+1)] + =404.00,406.00.

[0119] [ka] tert-Butyl N-[2-[(3-amino-5-bromopyridin-2-yl)oxy]ethyl]-N-(propan-2-yl)carbamate: To a solution of tert-butyl N-[2-[(5-bromo-3-nitropyridin-2-yl)oxy]ethyl]-N-(propan-2-yl)carbamate (15.0 g, 37.1 mmol) in acetic acid (150 mL) was added iron powder (20.7 g, 371 mmol) at ambient temperature. After stirring for an additional hour at ambient temperature, the resulting mixture was filtered and the filter cake was washed with tetrahydrofuran (4×100 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with 20% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless solid (12.0 g, 86%): 1 H NMR(400MHz,CD3OD)δ 7.40(d,J=2.2Hz,1H),7.04(d,J=2.2Hz,1H),4.40(t,J=6.3Hz,2H),4.25-3.99 (m,1H),3.52(t,J=6.3Hz,2H),1.46(s,9H),1.17(d,J=6.8Hz,6H);MS:[(M+1)] + =374.10,376.10.

[0120] [ka] tert-Butyl (2-((5-bromo-3-(methylsulfonamido)pyridin-2-yl)oxy)ethyl)(isopropyl)carbamate: To a solution of tert-butyl N-[2-[(3-amino-5-bromopyridin-2-yl)oxy]ethyl]-N-(propan-2-yl)carbamate (18.8 g, 50.3 mmol) in pyridine (400 mL) was added methanesulfonyl chloride (8.63 g, 75.4 mmol) at ambient temperature. After stirring at ambient temperature for 6 h, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with 3% to 25% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless solid (16.3 g, 72%): 1 H NMR(400MHz,DMSO-d6)δ 9.41(s,1H),8.05(d,J=2.2Hz,1H),7.79(d,J=2.2Hz,1H),4.35(t,J=6.3Hz,2H),4.15(s ,1H),3.43(t,J=6.3Hz,2H),3.11(s,3H),1.39(s,9H),1.09(d,J=6.8Hz,6H);MS:[(M+1)] + =452.00,454.00.

[0121] [ka] tert-Butyl (2-((5-bromo-3-(ethylsulfonamido)pyridin-2-yl)oxy)ethyl)(isopropyl)carbamate: To a stirred solution of tert-butyl (2-((3-amino-5-bromopyridin-2-yl)oxy)ethyl)(isopropyl)carbamate (5.00 g, 13.4 mmol) in pyridine (120 mL) was added ethanesulfonyl chloride (5.15 g, 40.1 mmol) dropwise at ambient temperature. After stirring at ambient temperature for 6 hours under nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 3% to 25% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a pale yellow solid (3.78 g, 61%): 1H NMR(400MHz,CD3OD)δ 7.92(s,1H),7.87(s,1H),4.48(t,J=6.6Hz,2H),4.25-4.20(m,1H),3.54(t,J=6.6Hz,2H),3 .13(t,J=7.3Hz,2H),1.49(s,9H),1.35(t,J=7.4Hz,3H),1.19(d,J=6.8Hz,6H);MS:[(M+1)] + =466.10,468.10.

[0122] [ka] tert-Butyl N-[2-[(5-bromo-3-iodopyridin-2-yl)oxy]ethyl]-N-isopropylcarbamate: To a solution of 5-bromo-3-iodopyridin-2-ol (10.0 g, 33.3 mmol) in anhydrous tetrahydrofuran (300 mL), triphenylphosphine (11.4 g, 43.3 mmol), tert-butyl N-(2-hydroxyethyl)-N-isopropylcarbamate (8.80 g, 43.3 mmol) and isopropyl azodiformate (8.80 g, 43.4 mmol) were added dropwise at 0° C. The resulting mixture was stirred at ambient temperature under nitrogen atmosphere for an additional 16 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with 2% to 10% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless oil (14.0 g, 87%): 1 H NMR(400MHz,CDCl3)δ 8.14(s,2H),4.43(t,J=6.4Hz,2H),4.38-3.96(m,1H),3.50(t,J=6.4Hz,2H),1.49(s,9H),1.19(d,J=6.8Hz,6H);MS:[(M+1)] + =484.95,486.95.

[0123] [ka] tert-Butyl (2-((5-bromo-3-((1-methylethyl)sulfonamido)pyridin-2-yl)oxy)ethyl)(isopropyl)carbamate: To a mixture of tert-butyl (2-((5-bromo-3-iodopyridin-2-yl)oxy)ethyl)(isopropyl)carbamate (5.00 g, 10.3 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.80 g, 3.10 mmol) and propane-2-sulfonamide (1.50 g, 12.4 mmol) in toluene (125 mL) was added tripotassium phosphate (10.9 g, 51.5 mmol) and tris(dibenzylideneacetone)dipalladium-chloroform adduct (1.10 g, 1.10 mmol) at ambient temperature. The resulting mixture was stirred at 100° C. for 48 hours under an argon atmosphere. After cooling to ambient temperature, the resulting mixture was filtered. The filter cake was washed with ethyl acetate (3×20 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with 1% to 20% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless solid (1.90 g, 39%): 1 H NMR(400MHz,CDCl3)δ 7.94(d,J=2.1Hz,1H),7.89(d,J=2.2Hz,1H),4.44(t,J=6.3Hz,2H),4.11(s,1H),3.48(t,J=6.3H z,2H),3.24-3.30(m,1H),1.48(s,9H),1.41(d,J=6.8Hz,6H),1.14(d,J=6.8Hz,6H);MS:[(M+1)] + =480.20,482.20.

[0124] [ka] N-(5-Bromo-2-[2-[(propan-2-yl)amino]ethoxy]pyridin-3-yl)methanesulfonamide: tert-Butyl N-[2-[(5-bromo-3-methanesulfonamidopyridin-2-yl)oxy]ethyl]-N-(propan-2-yl)carbamate (3.00 g, 6.63 mmol) in dichloromethane (5.00 mL) was treated with hydrogen chloride (20.0 mL, 4 M in 1,4-dioxane) at ambient temperature for 40 minutes. The resulting mixture was concentrated under reduced pressure. The residue was basified to pH=8 with saturated aqueous sodium bicarbonate (30.0 mL). The resulting mixture was extracted with ethyl acetate (6×200 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with 1% to 10% methanol in dichloromethane. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless solid (1.20 g, 50%): 1 H NMR(400MHz,DMSO-d6)δ 7.68(d,J=2.3Hz,1H),7.61(d,J=2.3Hz,1H),5.75(s,1H),4.36(t,J=5.2Hz,2H),3.1 9-3.12(m,1H),3.07(t,J=5.1Hz,2H),2.84(s,3H),1.15(d,J=6.4Hz,6H);MS:[(M+1)] + =352.10,354.10.

[0125] The following intermediates were prepared according to the procedures described above:

[0126] [Table 3]

[0127] [ka] N-(2-(2-(isopropylamino)ethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide: To a solution of tert-butyl N-[2-[(5-bromo-3-methanesulfonamidopyridin-2-yl)oxy]ethyl]-N-(propan-2-yl)carbamate (2.00 g, 5.68 mmol) and bis(pinacolato)diboron (2.88 g, 11.4 mmol) in 1,4-dioxane (50.0 mL) was added potassium acetate (2.23 g, 22.7 mmol) and bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct (0.46 g, 0.57 mmol) at ambient temperature. After stirring at 90° C. for 2 h under nitrogen atmosphere, the mixture was concentrated under reduced pressure. The mixture was diluted with dichloromethane (100 mL). After filtration, the filter cake was washed with dichloromethane (3×10.0 mL). The filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography with the following conditions: Column: spherical C18, 20-40 μm, 330 g; Mobile phase A: water (plus 10 mM NH4HCO3), Mobile phase B: acetonitrile; Flow rate: 65 mL / min; Gradient (B%): 5%-22%, 6 min; 22%-40%, 20 min; 40%-95%; 2 min; 95%, 5 min; Detector: UV 254 nm; Rt: 15 min. Fractions containing the desired product were collected and concentrated under reduced pressure to give the title compound as an off-white solid (1.57 g, 87%): 1 H NMR(400MHz,CDCl3)δ 8.27(d,J=1.7Hz,1H),8.06(d,J=1.7Hz,1H),4.51(t,J=5.2Hz,2H),3.05-2.9 9(m,5H),2.95-2.84(m,1H),1.33(s,12H),1.11(d,J=6.3Hz,6H);MS:[(M+1)] + =400.30.

[0128] [ka] N-(5-(7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)propane-2-sulfonamide: N-[5-bromo-2-[2-(isopropylamino)ethoxy]pyridin-3-yl]propane-2-sulfonamide in 1,4-dioxane (50.0 mL) To a solution of ]pyridin-3-yl]propane-2-sulfonamide (2.00 g, 5.26 mmol) was added bis(pinacolato)diboron (4.01 g, 15.8 mmol), potassium acetate (2.06 g, 21.1 mmol) and bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct (0.34 g, 0.42 mmol) at ambient temperature. The resulting mixture was stirred at 90° C. for 3 hours under nitrogen atmosphere. The resulting mixture was cooled to ambient temperature, followed by the addition of 8-bromo-7-fluoro-3-methylspiro[cyclobutane-1,1-pyrrolo[2,3-c]quinolin]-2-one (1.26 g, 3.76 mmol), water (12.5 mL), sodium carbonate (0.80 g, 7.55 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.43 g, 0.38 mmol). The resulting mixture was stirred at 85° C. for 6 hours under a nitrogen atmosphere. After cooling to ambient temperature, the resulting mixture was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography with the following conditions: Column: spherical C18, 20-40 μm, 120 g; Mobile phase A: water (plus 10 mM NH4HCO3), Mobile phase B: acetonitrile; Flow rate: 45 mL / min; Gradient (%B): 5%, 2 min; 5%-25%, 8 min; 25%-39%, 9 min; 39%, 10 min; 39%-95%; 3 min; 95%, 2 min; Detector: UV 254 nm; Rt: 21 min. Fractions containing the desired product were collected and concentrated under reduced pressure to give the title compound as a colorless solid (1.66 g, 80%): 1H NMR(400MHz,DMSO-d6)δ 8.88(s,1H),8.35-8.31(m,2H),8.07(s,1H),7.99(s,1H),7.96(s,1H),4.55(br,1H),4.44(t,J=5.2Hz,2H),3. 35-3.30(m,4H),2.93-2.79(m,5H),2.55-2.38(m,4H),1.29(d,J=7.2Hz,6H),1.02(d,J=6.0Hz,6H);MS:[(M+1)] + =556.30.

[0129] [ka] N-(5-(7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)propane-2-sulfonamide hydrochloride. A solution of N-(5-[7-fluoro-3-methyl-2-oxospiro[cyclobutane-1,1-pyrrolo[2,3-c]quinoline]-8-yl]-2-[2-(isopropylamino)ethoxy]pyridin-3-yl)propane-2-sulfonamide (1.66 g, 2.99 mmol) in dilute aqueous hydrochloric acid (392 mL, 3.14 mmol, 0.008 M) and acetonitrile (79.0 mL) was lyophilized to give the title compound as a yellow solid (1.76 g, 100%): 1 H NMR(400MHz,DMSO-d6)δ 9.45(s,1H),9.02(br,2H),8.90(s,1H),8.40(s,1H),8.32(d,J=8.4 Hz,1H),8.16(s,1H),8.00(d,J=8.4Hz,1H),4.65(t,J=4.4Hz,2H),3.54-3.40(m,3H),3 .31(s,3H),2.91(t,J=11.2Hz,2H),2.55-2.45(m,5H),1.34-1.30(m,12H);MS:[(M+1)] + =556.30.

[0130] In a similar manner, or by effecting a palladium(II) couple with intermediates CC108 and CC110, the following compounds Example 569 and Example 570 were obtained.

[0131] [Table 4] TIFF0007595959000032.tif152170TIFF0007595959000033.tif177170TIFF0007595959000034.tif158170

[0132] [ka] 1-(tert-butyl) 3-methyl 3-(6-bromo-7-fluoro-3-nitroquinolin-4-yl)azetidine-1,3-dicarboxylate: To a solution of freshly prepared lithium diisopropylamide (137 mmol) in anhydrous tetrahydrofuran (110 mL) was added a solution of 1-tert-butyl-3-methylazetidine-1,3-dicarboxylate (29.3 g, 137 mmol) in tetrahydrofuran (100 mL) at -78 °C. After stirring for 1 h, a solution of 6-bromo-4-chloro-7-fluoro-3-nitroquinoline (32.0 g, 105 mmol) in tetrahydrofuran (100 mL) was added to the reaction mixture over 20 min. The resulting mixture was slowly warmed to 0 °C for 2 h. The reaction was quenched with saturated aqueous ammonium chloride (20.0 mL) and diluted with water (800 mL). The resulting mixture was extracted with ethyl acetate (3×150 mL). The combined organic layers were washed with brine (2×100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 5% to 20% ethyl acetate in petroleum ether to give the title compound as a pale yellow solid (25.0 g, 49%): 1H NMR(400MHz,DMSO-d6)δ 9.35(s,1H),8.21(d,J=9.3Hz,1H),8.14(d,J=7.1Hz,1H),4.18-4.11(m,2H),3.87-3.74(m,2H),3.66(s,3H),1.37(s,9H);MS:[(M+1)] + =484.20,486.20.

[0133] [ka] tert-Butyl 8'-bromo-7'-fluoro-2'-oxo-2',3'-dihydrospiro[azetidine-3,1'-pyrrolo[2,3-c]quinoline]-1-carboxylate: To a solution of 1-tert-butyl 3-methyl 3-(6-bromo-7-fluoro-3-nitroquinolin-4-yl)azetidine-1,3-dicarboxylate (12.0 g, 24.8 mmol) in acetic acid (300 mL) was added iron powder (9.69 g, 174 mmol) at ambient temperature. After stirring at ambient temperature for 3 hours, the resulting mixture was concentrated under reduced pressure. The residue was taken up in water (200 mL) and extracted with ethyl acetate (4 x 100 mL). The combined organic layers were washed with brine (2 x 100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 1% to 5% methanol in dichloromethane to give the title compound as a colorless solid (10.4 g, 99%): 1 H NMR(400MHz,DMSO-d6)δ 11.02(br,1H),8.71(s,1H),8.24(d,J=7.3Hz,1H),8.03(d,J=10.1Hz,1H),4.29(d,J=9.0Hz,2H),4.21(d,J=9.0Hz,2H),1.49(s,9H);MS:[(M+1)] + =422.20,424.20.

[0134] [ka] tert-Butyl 8'-bromo-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[azetidine-3,1'-pyrrolo[2,3-c]quinoline]-1-carboxylate: To a stirred solution of tert-butyl 8-bromo-7-fluoro-2-oxo-2,3-dihydrospiro[azetidine-3,1-pyrrolo[2,3-c]quinoline]-1-carboxylate (4.22 g, 9.99 mmol) in N,N-dimethylformamide (100 mL) was added sodium hydride (0.52 g, 13.0 mmol, 60% dispersed in mineral oil) under a nitrogen atmosphere at 0° C. The resulting mixture was stirred at ambient temperature for 1 hour followed by the addition of iodomethane (1.70 g, 12.0 mmol). After stirring at ambient temperature for an additional hour, the reaction was quenched with saturated aqueous ammonium chloride (20.0 mL) and diluted with water (1.00 L). The precipitated solid was collected by filtration and washed with water (3×30.0 mL) and hexanes (2×30.0 mL). The resulting solid was dried under infrared light to give the title compound as a pale yellow solid (3.93 g, 90%): 1 H NMR(400MHz,CDCl3)δ 8.71(s,1H),8.47(d,J=7.0Hz,1H),7.94(d,J=9.1Hz,1H),4.54(d,J=9.1Hz,2H),4.31(d,J=9.0Hz,2H),3.40(s,3H),1.56(s,9H);MS:[(M+1)] + =436.15,438.15.

[0135] [ka] 8-Bromo-7-fluoro-3-methyl-2,3-dihydrospiro[azetidine-3,1-pyrrolo[2,3-c]quinoline]-2-one: tert-butyl in dichloromethane (100 mL) A solution of 8-bromo-7-fluoro-3-methyl-2-oxo-2,3-dihydrospiro[azetidine-3,1-pyrrolo[2,3-c]quinoline]-1-carboxylate (3.93 g, 9.01 mmol) and trifluoroacetic acid (20.0 mL) in dichloromethane (100 mL) was stirred at ambient temperature for 5 hours. The resulting mixture was concentrated under reduced pressure. The residue was basified to pH=8 with saturated aqueous sodium bicarbonate. The resulting mixture was extracted with ethyl acetate (6×300 mL). The combined organic layers were washed with brine (2×300 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to give the title compound as a pale yellow solid (3.00 g, 99%): 1 H NMR(400MHz,DMSO-d6)δ 9.56(d,J=7.7Hz,1H),8.92(s,1H),8.02(d,J=10.2Hz,1H),4.18(d,J=7.5Hz,2H),3.59(d,J=7.5Hz,2H),3.29(s,3H);MS:[(M+1)] + =335.95,337.95.

[0136] [ka] 8'-Bromo-7'-fluoro-1-isopropyl-3'-methylspiro[azetidin-3,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one: To a stirred solution of 8'-bromo-7'-fluoro-3'-methylspiro[azetidin-3,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one (100 mg, 0.30 mmol) in ethanol (8.00 mL) and acetone (4.00 mL) was added sodium cyanoborohydride (94.0 mg, 1.50 mmol) at ambient temperature. The resulting mixture was stirred at 50° C. for 3 hours under nitrogen atmosphere. The resulting mixture was purified by reverse-phase flash chromatography using the following conditions: Column: spherical C18, 20-40 μm, 120 g; Mobile phase A: water (plus 10 mM NH4HCO3), Mobile phase B: acetonitrile; Flow rate: 50 mL / min; Gradient (B): 5%-20%, 6 min; 20%-50%, 30 min; 50%-95%, 5 min; 95%, 5 min; Detector: UV 254 nm. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless solid (85.0 mg, 77%): 1 H NMR: 1 H NMR(400MHz,DMSO-d6)δ 9.84(d,J=8.0Hz,1H),8.93(s,1H),8.00(d,J=10.2Hz,1H),3.69(d,J=7.6Hz,2H),3.4 6(d,J=7.3Hz,2H),3.30(s,3H),2.63-2.56(m,1H),1.01(d,J=6.1Hz,6H);MS:[(M+1)] + =378.10,380.10.

[0137] [ka] N-[5-[7-fluoro-3-methyl-2-oxo-1-(propan-2-yl)-2,3-dihydrospiro[azetidine-3,1-pyrrolo[2,3-c]quinoline]-8-yl]-2-[2-[(propan-2-yl)amino]ethoxy]pyridin-3-yl]methanesulfonamide: 8-Bromo-7-fluoro-3-methyl-1-(propan-2-yl)-2,3-dihydrospiro[azetidine-3,1-pyrrolo[ To a solution of 2,3-c]quinolin]-2-one (80.0 mg, 0.21 mmol) and N-(2-[2-[(propan-2-yl)amino]ethoxy]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide (169 mg, 0.42 mmol) was added sodium carbonate (33.6 mg, 0.32 mmol) and tetrakis(triphenylphosphine)palladium(0) (24.3 mg, 0.021 mmol). After stirring at 80° C. for 2 hours under nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=10 / 1, v / v) to give the crude product, which was further purified by reversed-phase flash chromatography with the following conditions: Column: spherical C18, 20-40 μm, 120 g; Mobile phase A: water (plus 10 mM NH4HCO3), Mobile phase B: acetonitrile; Flow rate: 45 mL / min; Gradient (B%): 5%, 2 min; 5%-24%, 5 min; 24%-34%, 9 min; 34%, 8 min; 34%-95%; 3 min; 95%, 2 min; Detector: UV 254 nm; Rt: 21 min. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless solid (65.0 mg, 54%): 1H NMR(400MHz,DMSO-d6)δ 9.66(d,J=8.9Hz,1H),8.89(s,1H),8.25(t,J=1.9Hz,1H),7.99-7.91(m ,2H),4.42(t,J=5.4Hz,2H),3.76(d,J=7.2Hz,2H),3.47(d,J=7.3Hz,2H) ,3.31(s,3H),3.02(s,3H),2.96(t,J=5.4Hz,2H),2.92-2.84(m,1H),2.6 2-2.53(m,1H),1.05(d,J=6.3Hz,6H),0.97(d,J=6.1Hz,6H);MS:[(M+1)] + =571.25.

[0138] [ka] Methyl 1-(6-bromo-7-fluoro-3-nitroquinolin-4-yl)-3-methoxycyclobutane-1-carboxylate: To a solution of freshly prepared lithium diisopropylamide (10.6 mmol) in anhydrous tetrahydrofuran (100 mL) was added methyl 3-methoxycyclobutane-1-carboxylate (1.53 g, 10.6 mmol) at -78°C. After stirring for an additional hour, a solution of 6-bromo-4-chloro-7-fluoro-3-nitroquinoline (2.50 g, 8.18 mmol) in tetrahydrofuran (5.00 mL) was added over 5 minutes. The resulting mixture was allowed to warm slowly to 0°C and then quenched with saturated aqueous ammonium chloride (100 mL). The resulting mixture was diluted with water (1.00 L) and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with brine (2×200 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with 5% to 50% ethyl acetate in petroleum ether to give the title compound as a brown syrup (720 mg, 21%): 1H NMR(400MHz,DMSO-d6)δ9.25(s,1H),8.31(d,J=7.3Hz,1H),8.17(d,J=9.3Hz,1H),4.16- 4.13(m,1H),3.71(s,3H),3.11(s,3H),2.47-2.38(m,2H),2.00-1.89(m,2H);MS:[(M+1)] + =413.20,415.20.

[0139] [ka] 8'-Bromo-7'-fluoro-3-methoxyspiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one: To a solution of methyl 1-(6-bromo-7-fluoro-3-nitroquinolin-4-yl)-3-methoxycyclobutane-1-carboxylate (720 mg, 1.74 mmol) in acetic acid (10.0 mL) was added iron powder (681 mg, 12.2 mmol). The resulting mixture was stirred at ambient temperature for 3 hours. The resulting mixture was diluted with water (150 mL) and extracted with ethyl acetate (4 x 50.0 mL). The combined organic layers were washed with brine (2 x 50.0 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 5% to 30% ethyl acetate in petroleum ether to give the title compound as a pale yellow solid (550 mg, 89%): 1 H NMR(400MHz,CDCl3)δ 8.93(s,0.45H),8.88(d,J=7.2Hz,0.55H),8.84(s,1H),8.78(s,0.55H),8.27(d,J=7.0Hz,0.45H)7.92(d,J=9 MS:[(M+1)] + =351.00,353.00.

[0140] [ka] 8'-Bromo-7'-fluoro-3-methoxy-3'-methylspiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one: A solution of 8-bromo-7-fluoro-3-methoxy-2,3-dihydrospiro[cyclobutane-1,1-pyrrolo[2,3-c]quinolin]-2-one (550 mg, 1.56 mmol) in N,N-dimethylformamide (10.0 mL) was treated with sodium hydride (81.4 mg, 2.04 mmol 60% dispersed in mineral oil) at 0° C. for 0.5 h, followed by the dropwise addition of iodomethane (265 mg, 1.87 mmol) over 2 min at 0° C. After stirring at ambient temperature for an additional 1 h, the reaction was quenched with saturated aqueous ammonium chloride (20.0 mL) and diluted with water (150 mL). The resulting mixture was extracted with ethyl acetate (3×50.0 mL). The combined organic layers were washed with brine (2×30.0 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 5%-10% ethyl acetate in petroleum ether to give the title compound as a yellow solid (500 mg, 87%): MS: [(M+1)] + =365.10,367.10.

[0141] [ka] 8'-Bromo-7'-fluoro-3-hydroxy-3'-methylspiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one: To a stirred solution of 8'-bromo-7'-fluoro-3-methoxy-3'-methylspiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one (900 mg, 2.46 mmol) in dichloromethane (20.0 mL) was added boron tribromide (24.6 mL, 24.6 mmol, 1 M in dichloromethane) dropwise at -78°C under nitrogen atmosphere. The resulting mixture was allowed to warm slowly to ambient temperature. The resulting mixture was stirred at ambient temperature under nitrogen atmosphere for 2 hours. The mixture was neutralized with saturated aqueous sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine (3×100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 1% to 5% methanol in dichloromethane. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless solid (530 mg, 62%): 1 H NMR(400MHz,DMSO-d6)δ 8.96-8.89(m,1.6H),8.32(d,J=7.4Hz,0.4H),8.05-7.98(m,1H),5.99(d,J=6.5Hz,0.6H),5.73(d,J=5.7Hz,0.4H),4.97-4.87(m,0. MS:[(M+1)] + =351.00,353.00.

[0142] [ka] 3-(Benzyloxy)-8'-bromo-7'-fluoro-3'-methylspiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one: To a solution of 8'-bromo-7'-fluoro-3-hydroxy-3'-methylspiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one (100 mg, 0.29 mmol) in N,N-dimethylformamide (5.00 mL) was added sodium hydride (13.7 mg, 0.35 mmol, 60% dispersed in mineral oil) under nitrogen at 0° C. The resulting mixture was stirred at 25° C. for 1 h, followed by the addition of benzyl bromide (97.4 mg, 0.57 mmol) at 0° C. After stirring at 25° C. for an additional hour, the reaction was quenched with saturated aqueous ammonium chloride solution (10.0 mL). The resulting mixture was diluted with water (100 mL) and extracted with ethyl acetate (3×50.0 mL). The combined organic layers were washed with brine (2×50.0 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=25 / 1, v / v) to give the title compound as a yellow solid (64.0 mg, 51%): 1 H NMR(400MHz,DMSO-d6)δ 8.92(d,J=3.6Hz,1H),8.79(d,J=7.6Hz,0.5H),8.25(d,J=7.2Hz,0.5H),8 .03(d,J=10.1Hz,1H),7.50(d,J=7.0Hz,1H),7.46-7.37(m,3H),7.37-7.3 0(m,1H),4.87-4.79(m,0.5H),4.62-4.50(m,2.5H),3.30(d,J=5.7Hz,3H) ,2.98-2.90(m,1H),2.80(d,J=6.7Hz,2H),2.72-2.64(m,1H);MS:[(M+1)] + =441.00,443.00.

[0143] [ka] N-(5-(3-(benzyloxy)-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide: 3-(benzyloxy)-8'-bromo-7'-fluoro-3'-methylspiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl in water (1.00 mL) and 1,4-dioxane (4.00 mL). To a solution of N-[2-[2-(isopropylamino)ethoxy]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl]methanesulfonamide (69.5 mg, 0.17 mmol) was added sodium carbonate (15.4 mg, 0.15 mmol) and tetrakis(triphenylphosphine)palladium(0) (33.5 mg, 0.029 mmol). After stirring at 80° C. for 2 h under nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=10 / 1, v / v) to give the title compound as a pale yellow solid (55.0 mg, 60%): MS: [(M+1)] + =634.55.

[0144] [ka] Cis-N-(5-(3-(benzyloxy)-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide (Example 572) and trans-N-(5-(3-(benzyloxy)-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide (Example 567). The above N-(5-(3-(benzyloxy)-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide (55.0 mg, 0.087 mmol) was separated by preparative chiral HPLC under the following conditions: (Column: CHIRALPAK ID, 2x25cm (5μm); Mobile phase A: methyl tert-butyl ether (plus 0.2% isopropylamine), Mobile phase B: EtOH; Flow rate: 17mL / min; Gradient: 10% B in 13min; Detector: UV220 / 254nm) cis-N-(5-(3-(benzyloxy)-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide (Example 572, RT1: 8.70min) was obtained as a pale yellow solid (15.3mg, 28%): 1H NMR(400MHz,DMSO-d6)δ 8.90(s,1H),8.29(s,1H),8.09(d,J=8.3Hz,1H),8.02(d,J=1.9Hz,1H),7. 98(d,J=12.1Hz,1H),7.42-7.34(m,4H),7.32-7.27(m,1H),4.90-4.82(m,1 H),4.53(s,2H),4.47(t,J=5.4Hz,2H),3.32(s,3H),3.06(s,3H),3.05-2. 88(m,5H),2.68(dd,J=13.9,6.2Hz,2H),1.08(d,J=6.2Hz,6H);MS:[(M+1)] + = 634.50 and trans-N-(5-(3-(benzyloxy)-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide (Example 567, RT2: 11.2 min) was obtained as a colorless solid (12.6 mg, 23%): 1 H NMR(400MHz,DMSO-d6)δ 8.88(s,1H),8.59(d,J=8.3Hz,1H),8.33(s,1H),8.02-7.94(m,2H),7.36-7.21(m,5H ),4.58(q,J=6.3Hz,1H),4.44(t,J=5.4Hz,2H),4.41-4.33(m,1H),3.28(s,3H),3.05( s,3H),2.00-3.94(m,3H),2.92-2.84(m,1H),2.83-2.74(m,1H),2.69(dd,J=13.1,5. 8Hz,2H),2.59-2.54(m,1H),1.35(d,J=6.4Hz,3H),1.05(d,J=6.3Hz,6H);MS:[(M+1)] + =634.55.

[0145] [ka] Decyl 3-oxocyclobutane-1-carboxylate: To a stirred solution of 3-methylcyclobutane-1-carboxylic acid (3.00 g, 26.3 mmol) and 1-decanol (4.16 g, 26.3 mmol) in dichloromethane (90.0 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (7.56 g, 39.4 mmol) and 4-dimethylaminopyridine (0.32 g, 2.62 mmol) at ambient temperature. The resulting mixture was stirred at 25° C. for 16 h and quenched with water (30.0 mL). The resulting mixture was extracted with dichloromethane (3×100 mL). The combined organic layers were washed with brine (2×50.0 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with 1% to 8% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a pale yellow oil (3.10 g, 47%): 1 H NMR(400MHz,CDCl3)δ 4.15(t,J=6.7Hz,2H),3.47-3.35(m,2H),3.35-3.15(m,3H),1.69-1.61(m,2H),1.39-1.22(m,14H),0.88(t,J=6.7Hz,3H);MS:[(M+1)] + =252.20.

[0146] [ka] Decyl 3-ethylidenecyclobutane-1-carboxylate: To a solution of ethyltriphenylphosphonium bromide (17.3 g, 46.5 mmol) in dimethylsulfoxide (300 mL) was added potassium t-butoxide (4.94 g, 44.1 mmol) portionwise at 14° C. The resulting mixture was stirred under nitrogen atmosphere at 25° C. for 0.5 h, followed by the dropwise addition of decyl 3-oxocyclobutane-1-carboxylate (8.00 g, 31.5 mmol) over 2 min at 14° C. After stirring at 25° C. for 4 h, the reaction was quenched with saturated aqueous ammonium chloride solution (20.0 mL) at 0° C. The resulting mixture was diluted with water (1.00 L) and extracted with ethyl acetate (3×200 mL). The combined organic layers were washed with brine (2×100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with 1% to 5% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless oil (1.70 g, 21%): 1 H NMR(400MHz,CDCl3)δ 5.22-5.14(m,1H),4.09(t,J=6.7Hz,2H),3.10(tt,J=9.2,7.2Hz,1H),2.96-2.79(m,4H), 1.67-1.58(m,2H),1.49(dq,J=6.0,2.0Hz,3H),1.39-1.20(m,14H),0.88(t,J=6.7Hz,3H).

[0147] [ka] Decyl 3-ethylcyclobutane-1-carboxylate: To a stirred solution of decyl 3-ethylidenecyclobutane-1-carboxylate (700 mg, 4.94 mmol) in methanol (10.0 mL) was added anhydrous Pd / C (70.0 mg, 10% palladium on charcoal) at ambient temperature. After stirring under hydrogen atmosphere (2 atmospheres) at ambient temperature for 16 hours, the resulting mixture was filtered. The filter cake was washed with methanol (3×20.0 mL). The filtrate was concentrated under reduced pressure to give the title compound as a pale yellow oil (666 mg, 95%):1 H NMR(400MHz,CDCl3)δ4.10-4.02(m,2H),3.10-2.87(m,1H),2.40-2.22(m,2H),2.16-2. 03(m,1H),1.91-1.76(m,2H),1.67-1.56(m,2H),1.48-1.21(m,16H),0.92-0.75(m,6H).

[0148] [ka] Decyl 1-(6-bromo-7-fluoro-3-nitroquinolin-4-yl)-3-ethylcyclobutane-1-carboxylate: To a solution of freshly prepared lithium diisopropylamide (2.45 mmol) in anhydrous tetrahydrofuran (20.0 mL) was added decyl 3-ethylcyclobutane-1-carboxylate (657 mg, 2.45 mmol) at −78° C. under nitrogen atmosphere. The resulting mixture was stirred for 1 h, followed by the addition of 6-bromo-4-chloro-7-fluoro-3-nitroquinoline (575 mg, 1.88 mmol) at −78° C. After stirring for an additional 1 h at 25° C., the reaction was quenched with saturated aqueous ammonium chloride solution (10.0 mL). The resulting mixture was diluted with water (20.0 mL) and separated. The aqueous layer was extracted with ethyl acetate (5×30 mL). The combined organic layers were washed with brine (4×30.0 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 3% to 9% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a yellow oil (450 mg, crude): MS: [(M+1)] + =537.25,539.25.

[0149] [ka] 8'-Bromo-3-ethyl-7'-fluorospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one: A mixture of crude decyl 1-(6-bromo-7-fluoro-3-nitroquinolin-4-yl)-3-ethylcyclobutane-1-carboxylate (450 mg, 0.84 mmol) and iron powder (327 mg, 5.86 mmol) in acetic acid (8.00 mL) was stirred at ambient temperature for 16 hours. The resulting mixture was filtered and the filter cake was washed with tetrahydrofuran (5x300 mL). The filtrate was concentrated under reduced pressure. The residue was basified to pH=8 with saturated aqueous sodium bicarbonate. The resulting mixture was extracted with ethyl acetate (5x100 mL). The combined organic layers were washed with brine (50.0 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=15 / 1, v / v) to give the title compound as a yellow solid (40.0 mg, 14%): 1 H NMR(400MHz,DMSO-d6)δ 10.76(d,J=5.3Hz,1H),8.67(d,J=1.7Hz,1H),8.45(d,J=7.2Hz,0.4H),8.39(d,J=7.4Hz,0.6H),7.98(dd,J=10.1,3. MS:[(M+1)] + =349.05,351.05.

[0150] [ka] 8'-Bromo-3-ethyl-7'-fluoro-3'-methylspiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one: To a solution of 8'-bromo-3-ethyl-7'-fluorospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-2'(3'H)-one (35.0 mg, 0.10 mmol) in N,N-dimethylformamide (3.00 mL) was added sodium hydride (5.21 mg, 0.13 mmol, 60% dispersed in mineral oil) under nitrogen at 0° C. The resulting mixture was stirred at 25° C. for 30 minutes, followed by the addition of iodomethane (21.4 mg, 0.15 mmol) at 0° C. After stirring at 25° C. for an additional 40 min, the reaction was quenched with saturated aqueous ammonium chloride solution (20.0 mL). The resulting mixture was diluted with water (100 mL) and extracted with ethyl acetate (4×100 mL). The combined organic layers were washed with brine (4×100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=20 / 1, v / v) to give the title compound as a yellow solid (30.0 mg, 83%): 1 H NMR(400MHz,DMSO-d6)δ 8.90(d,J=2.9Hz,1H),8.49(d,J=7.4Hz,0.4H),8.42(d,J=7.4Hz,0.6H),8.02(dd,J=10.1,3.1Hz,1H),3.29(d,J=4. MS:[(M+1)] + =363.05,365.05.

[0151] [ka] N-(5-(3-ethyl-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide: 8'-bromo-3-ethyl-7'-fluoro-3'-methylspiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline] in water (0.75 mL) and 1,4-dioxane (3.00 mL). To a solution of N-[2-[2-(isopropylamino)ethoxy]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl]methanesulfonamide (165 mg, 0.41 mmol) was added sodium carbonate (17.5 mg, 0.17 mmol) and tetrakis(triphenylphosphine)palladium(0) (31.8 mg, 0.028 mmol). After stirring at 80° C. for 2 hours under nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=10 / 1, v / v) to give the crude product, which was further purified by reverse-phase flash chromatography under the following conditions: Column: spherical C18, 20-40 μm, 120 g; Mobile phase A: water (plus 10 mM NH4HCO3), Mobile phase B: acetonitrile; Flow rate: 45 mL / min; Gradient (B%): 5%-25%, 7 min; 25%-45%, 25 min; 45%-65%, 8 min; 95%, 5 min; Detector: UV 254 nm. The fractions containing the desired product were collected at 17 min and concentrated under reduced pressure to give the title compound as a yellow solid (30.0 mg, 40%): MS: [(M+1)] + =556.20.

[0152] [ka] Cis-N-(5-(3-ethyl-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide (Example 573) and trans-N-(5-(3-ethyl-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl) -2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide (Example 566): The above N-(5-(3-ethyl-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide (30.0 mg) was separated by preparative chiral HPLC using the following conditions: Column: Chiralpak IC, 2 x 25 cm, 5 μm; Mobile phase A: Hexane / DCM=3 / 1 (plus 0.2% isopropylamine), Mobile phase B: EtOH; Flow rate: 20 mL / min; Gradient: 30% B in 15 min; Detector: UV 220 / 254 nm. The desired fractions were collected and concentrated under reduced pressure to give cis-N-(5-(3-ethyl-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide (Example 573, RT1: 10.94 min) as a colorless solid (12.8 mg, 43%): 1 H NMR(400MHz,DMSO-d6)δ 8.87(s,1H),8.32-8.22(m,2H),7.98(d,J=12.2Hz,2H),4.44(t,J=5.3Hz,2H),3.30(s,3H),3.04(s,3H),2.99(t,J=5.3Hz,2H),2.94 -2.78(m,4H),2.26(dd,J=12.2,5.7Hz,2H),1.75(t,J=7.2Hz,2H),1.07(d,J=6.3Hz,6H),0.89(t,J=7.3Hz,3H);MS:[(M+1)]+=556.25 and trans-N-(5-(3-ethyl-7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide (Example 566, RT2: 13.63 min) was obtained as a colorless solid (8.6 mg, 29%): 1 H NMR(400MHz,DMSO-d6)δ 8.88(s,1H),8.34-8.26(m,2H),8.01-7.93(m,2H),4.44(t,J=5.4Hz,2H),3.31(s,3H),3.05(s,3H),3.00(d,J=5.4Hz,2H),2.96-2.8 3(m,2H),2.70-2.60(m,2H),1.66(q,J=7.2,6.7Hz,2H),2.56-2.52(m,2H),1.07(d,J=6.2Hz,6H),0.89(t,J=7.3Hz,3H);MS:[(M+1)] + =556.20.

[0153] [ka] 1-(5-Bromo-3-nitropyridin-2-yl)-N,N-dimethylazetidin-3-amine: To a stirred solution of N,N-dimethylazetidin-3-amine hydrochloride (0.27 g, 2.08 mmol) and 5-bromo-2-chloro-3-nitropyridine (0.49 g, 2.08 mmol) in tetrahydrofuran (40.0 mL) was added diisopropylethylamine (0.67 g, 5.19 mmol) at ambient temperature. The resulting mixture was stirred for 3 h and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 3% to 9% ethyl acetate in petroleum ether. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a yellow solid (0.50 g, 59%): 1H NMR(400MHz,CDCl3)δ 8.37(d,J=2.2Hz,1H),8.29(d,J=2.2Hz,1H),4.20(ddd,J=10.0,7.0,1.2Hz,2H),3.9 3(ddd,J=9.9,5.1,1.2Hz,2H),3.16(tt,J=7.0,5.1Hz,1H),2.20(s,6H);MS:[(M+1)] + =301.00,303.00.

[0154] [ka] 1-(5-Bromo-3-nitropyridin-2-yl)-N,N-dimethylazetidin-3-amine. To a solution of 1-(5-Bromo-3-nitropyridin-2-yl)-N,N-dimethylpiperidin-4-amine (6.20 g, 20.7 mmol) in acetic acid (90.0 mL) was added iron powder (11.5 g, 206 mmol) at ambient temperature. The resulting mixture was stirred at ambient temperature for 2 hours. The resulting mixture was filtered and the filter cake was washed with tetrahydrofuran (3x100 mL). The filtrate was concentrated under reduced pressure. The residue was taken up in saturated aqueous sodium carbonate (100 mL) and extracted with ethyl acetate (3x100 mL). The combined organic layers were washed with brine (3x100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 2% to 4% methanol in dichloromethane to give the title compound as a grey solid (5.20 g, 92%): 1 H NMR(400MHz,CDCl3)δ 7.74(d,J=2.0Hz,1H),6.93(d,J=2.0Hz,1H),4.19-4.04(m,2H),3.93-3.88(m,2H),3.21-3.14(m,1H),2.24(s,6H);MS:[(M+1)] + =271.00,273.00.

[0155] [ka] N-(5-bromo-2-(3-(dimethylamino)azetidin-1-yl)pyridin-3-yl)methanesulfonamide: To a stirred solution of 5-bromo-2-[3-(dimethylamino)azetidin-1-yl]pyridin-3-amine (2.10 g, 7.77 mmol) and N,N-4-dimethylaminopyridine (77.0 mg, 0.63 mmol) in pyridine (70.0 mL) was added methanesulfonyl chloride (1.77 g, 15.5 mmol) dropwise at ambient temperature. After stirring at ambient temperature for 3 hours under a nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography with the following conditions: Column: spherical C18, 20-40 μm, 330 g; Mobile phase A: water (plus 10 mM NH4HCO3), Mobile phase B: acetonitrile; Flow rate: 65 mL / min; Gradient (B%): 5%-20%, 8 min; 20%-40%, 20 min; 40%-95%, 2 min; 95%, 5 min; Detector: UV 254 nm. The desired fraction was collected at 19 min and concentrated under reduced pressure to give the title compound as a colorless solid (1.40 g, 52%): 1 H NMR(400MHz,CD3OD)δ 7.92(d,J=2.2Hz,1H),7.61(d,J=2.2Hz,1H),4.27(dd,J=8.8,7.2Hz,2H),3.96( dd,J=9.0,5.6Hz,2H),3.24-3.16(m,1H),3.00(s,3H),2.20(s,6H);MS:[(M+1)] + =349.00,351.00.

[0156] [ka] N-(2-(3-(dimethylamino)azetidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide: To a solution of N-[5-bromo-2-[3-(dimethylamino)azetidin-1-yl]pyridin-3-yl]methanesulfonamide (1.00 g, 2.86 mmol) and 4-bis(pinacolato)diboron (2.18 g, 8.59 mmol) in 1,4-dioxane (30.0 mL) was added potassium acetate (1.12 g, 11.5 mmol) and bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct (351 mg, 0.43 mmol) at ambient temperature. The resulting mixture was stirred at 85° C. for 2 hours under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse flash chromatography under the following conditions: Column: spherical C18, 20-40 μm, 330 g; Mobile phase A: water (plus 10 mM NH4HCO3), Mobile phase B: acetonitrile; Flow rate: 65 mL / min; Gradient (B%): 5%-20%, 7 min; 20%-40%, 12 min; 40%-95%; 2 min; 95%, 5 min; Detector: UV 254 nm. The desired fraction was collected at 20 min and concentrated under reduced pressure to give the title compound as a yellow solid (800 mg, 71%): 1 H NMR(400MHz,DMSO-d6)δ 8.78(s,1H),8.18(d,J=1.5Hz,1H),7.50(d,J=1.6Hz,1H),4.19(t,J=8.0Hz,2H),3.93(dd, J=8.9,5.0Hz,2H),3.12-3.04(m,1H),2.99(s,3H),2.09(s,6H),1.27(s,12H);MS:[(M+1)] + =397.20.

[0157] [ka] N-(2-(3-(dimethylamino)azetidin-1-yl)-5-(3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)pyridin-3-yl)methanesulfonamide: 8-bromo-3-methyl-2,3-dihydrospiro[cyclobutane-1,1-pyrrolo[2,3-c]quinoline]-2-oxo in 1,4-dioxane (13.0 mL) and water (2.00 mL). To a solution of N-[2-[3-(dimethylamino)azetidin-1-yl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl]methanesulfonamide (600 mg, 1.51 mmol) was added sodium carbonate (160 mg, 1.51 mmol) and tetrakis(triphenylphosphine)palladium(0) (175 mg, 0.15 mmol). After stirring at 85° C. for 2 h under nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=8 / 1, v / v) to give the title compound as a pale yellow solid (350 mg, 69%): 1 H NMR(400MHz,DMSO-d6)δ 9.07(s,1H),8.80(s,1H),8.58(s,1H),8.33(s,1H),8.13(d,J=8.9Hz,1H),7.95(d,J=9.2Hz,1H),7.91(d,J=2.1Hz,1H),4.2 8-4.21(m,2H),4.02-3.95(m,2H),3.30(s,3H),3.14(s,4H),2.98-2.90(m,2H),2.60-2.52(m,4H),2.13(s,6H);MS:[(M+1)] + =507.20.

[0158] [ka] N-(2-(3-(dimethylamino)azetidin-1-yl)-5-(3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)pyridin-3-yl)methanesulfonamide hydrochloride: N- in dilute aqueous hydrochloric acid (115 mL, 0.69 mmol, 0.006 M) and acetonitrile (20.0 mL) A solution of (2-(3-(dimethylamino)azetidin-1-yl)-5-(3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinoline]-8'-yl)pyridin-3-yl)methanesulfonamide (350 mg, 0.69 mmol) was directly lyophilized to give the title compound as an orange solid (375 mg, 100%): 1 H NMR(400MHz,DMSO-d6)δ 10.77(s,1H),9.24(s,1H),8.83(s,1H),8.64(d,J=2.1Hz,1H),8.35(s,1H),8.17(d,J=8.9Hz,1H),8.02-7.94(m,2H),4.50-4.41(m,2H), 4.39-4.32(m,2H),4.27-4.16(m,1H),3.31(s,3H),3.18(s,3H),2.99-2.88(m,2H),2.82(d,J=4.1Hz,6H),2.63-2.52(m,4H);MS:[(M+1)] + =507.20.

[0159] On-target and off-target inhibitory activity ATM in Cell Western Assay: In the morning, MCF-7 breast cancer cells were plated in 384-well plates at a density of 10,000 cells (Corning, #356663), 25 μL cells per well. The next day, compounds were added to the plates using a pin tool (Echo 550) to a final concentration of 1 μM by 3-fold serial dilution (10 doses total). Etoposide (Sigma, #E1383) is then added to a final concentration of 100 μM. Plates were incubated at 37°C for 1 hour and cells were fixed by adding 25 μL of fixative (8% paraformaldehyde) for 20 minutes at ambient temperature. Cells were permeabilized by washing five times with 1X PBS (phosphate buffered saline) containing 0.1% Triton X-100, each wash for 5 minutes. The cells were then blocked by adding 50 μL of Odyssey blocking buffer (LI-COR, #927-40000) to the 384-well plate with shaking for 1.5 hours at ambient temperature. The blocking buffer was then removed and 20 μL of anti-pKAP1 antibody (Bethyl Laboratories, #A300-767A) (1 / 2000) solution was added to each well of the 384-well plate. The plate was incubated overnight at 4°C and then washed five times with 1X PBST (1X PBS with 0.1% Tween-20). Secondary antibody (IRDye 800CW goat anti-rabbit IgG, LI-COR, #926-32211) (1 / 5,000) solution containing DNA stain DRAQ5 (CST, #4084L) (1 / 5,000) (20 μL) was added to each well of the plate and the plate was incubated for 1 hour in the dark with gentle shaking. The cells were washed five times with 1X PBST (1X PBS with 0.1% Tween-20) at ambient temperature with gentle shaking in the dark. After the last wash, the wash solution was removed and the plate was placed upside down on a thin paper towel and centrifuged at 1000 rpm for 1 minute to absorb all the wash buffer. The bottom of the plate was washed with moist lint-free paper. The plate was immediately scanned using an ODYSSEY CLx (LI-COR).

[0160] DNA-PK enzyme-linked immunosorbent assay: On day 1, 96-well plates (ThermoFisher, Cat. No. 442404) were coated with GST-p53(1-101) peptide (purified by Pharmaron, BCS division) by diluting 3 μg of GST-p53 per well in 0.1 M Na2CO3 / NaHCO3 (pH 9.6). Plates were incubated overnight at 4°C. On day 2, the coating buffer was removed and plates were washed twice with PBST (1X PBS with 0.1% Tween-20). DNA-PK enzyme solution (Invitrogen, #PR9107A; final DNA-PK concentration: 0.1 μg / mL) was then added. Compounds were serially diluted (3-fold serial dilutions, 10 doses in total) to a final maximum concentration of 100 nM, and ATP solution (final ATP concentration: 20 μM) was added to the plates. Plates were incubated at 25°C for 1 h. Plates were washed three times with PBST (1X PBS containing 0.1% Tween-20) and blocked overnight at 4°C with a solution of PBST and 1% BSA. On the third day, plates were washed four times with PBST (1X PBS containing 0.1% Tween-20). Anti-phospho-p53 primary antibody (cell signaling Technology, #9286, phospho-p53 (Ser15) (16G8) mouse mAb) (1 / 1000) was added to each well. Plates were sealed, incubated for 1 hour at 37°C, and washed four times with PBST (1X PBS containing 0.1% Tween-20). HRP-conjugated secondary antibody (Cell signaling Technology, #7076, anti-mouse IgG, HRP-conjugated antibody) (1 / 1000) (100 μL) was added to each well. The plate was sealed with tape, incubated at 37°C for 30 minutes, and washed 4 times with PBST (1X PBS with 0.1% Tween-20). At this point, 100 μL of TMB (Cell signaling Technology, #7004) substrate was added to each well. The plate was sealed with tape and the plate was incubated at 37°C for 10 minutes. Stop solution (Cell signaling Technology, #7002) (100 μL) was added to each well and the plate was monitored for absorbance at 450 nm.

[0161] mTOR biochemical assays: mTOR kinase reactions were performed in 10 μL volumes in low volume 384-well plates. Typically, PerkinElmer model 6008260 plates were used. The composition of 1x kinase reaction buffer was: 50 mM HEPES pH 7.5, 0.01% Tween 20, 1 mM EGTA, 10 mM MnCl2, and 2 mM DTT. A solution of mTOR enzyme (ThermoFisher, #PR8683B; final mTOR concentration: 0.5 μg / mL) was added and compounds were serially diluted to a final maximum concentration of 100 nM (3-fold serial dilutions, 10 doses total). GFP-4E-BP1 (final concentration: 0.4 μM) and ATP solution (final ATP concentration: 3 μM) were added to the 384-well plate. The plate was incubated for 1 hour at 25° C., and 10 μL of EDTA solution (20 mM) and Tb-labeled anti-p4E-BP1 antibody (4 nM) in TR-FRET dilution buffer was added to each well. The plate was sealed, incubated for 30 minutes at 25° C., and read on a LanthaScreen™ plate reader configured for TRFRET.

[0162] PI3Kα and PI3Kδ biochemical assays: PI3K□ and PI3K□ kinase reactions were performed in 5 μL volumes in low volume 384-well plates. Typically PerkinElmer model 6008280 plates were used. 1x kinase reaction buffer consisted of 50 mM HEPES pH 7.5, 3 mM MgCl2, 0.03% CHAPS, 1 mM EGTA, 100 mM NaCl, and 2 mM DTT. PI3K□ (ThermoFisher, #PV4788; final PI3K□ concentration: 120 ng / mL) or PI3K□ enzyme solution (ThermoFisher, #PV6451; final PI3K□ concentration: 250 ng / mL) were added to the plate and compounds were added to a final maximum concentration of 100 nM (3-fold serial dilutions, 10 doses total), PIP2:3PS (final concentration: 10□g / mL) and ATP solution (final ATP concentration: 10 μM) in the 384-well plate. The plate was incubated for 1 hour at 25° C. ADP-Glo ​​Reagent Buffer (5 μL) was added to each well. The plate was sealed and incubated for 40 minutes at 25° C. ADP-Glo ​​Detection Buffer (10 μL) was added to each well and the plate was incubated for 40 minutes at 25° C. and read on a plate reader configured for luminescence.

[0163] In vitro hERG inhibition assay: hERG-T-REx™ HEK293 cells (Invitrogen, K1236) were generated by transfecting the hERG coding sequence in the Tet-regulated expression vector pT-Rex-DEST30 into cells expressing the Tet repressor (T-Rex™ HEK293), thereby producing cells that can be induced to express high levels of hERG channels. Cells were cultured in medium containing 85% DMEM, 10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES, 100 U / mL penicillin-streptomycin, 5 μg / mL blasticidin, and 400 μg / mL geneticin. Cells were split approximately three times a week using TrypLE™ Express (Gibco, 12604) and maintained at approximately 40% to approximately 80% confluence. Prior to the assay, cells were induced with 1 μg / mL doxycycline (Sigma, D9891) for 48 h. On the day of the experiment, induced cells were resuspended and plated at 5 × 10 cells per 6 cm cell culture dish before use. 5Cells were plated on glass coverslips. hERG channel-mediated currents were acquired by a manual patch clamp recording system equipped with an amplifier (HEKA, EPC10 and Molecular Devices, multiclamp 700B) and an inverted phase contrast microscope (Olympus, IX51 / 71 / 73). Glass pipettes were prepared by a micropipette puller (Sutter, P97 and Narishige, PC-10) and qualified with pipette resistances ranging from 2 to 4 M□. The internal pipette solution was 140 mM KCl, 2 mM MgCl2, 10 mM EGTA, 5 mM MgATP, and 10 mM HEPES (pH adjusted to 7.35 with KOH), and the external buffer was 132 mM NaCl, 4 mM KCl, 3 mM CaCl2, 0.5 mM MgCl2, 11.1 mM glucose, and 10 mM HEPES (pH adjusted to 7.35 with NaOH). The whole-cell configuration was maintained with continuous monitoring of access resistance (<15M□). hERG currents were evoked by depolarizing membrane to +30 mV for 4.8 s, and the voltage was returned to -50 mV for 5.2 s to remove inactivation and measure inactivation tail current. The maximum tail current size was used to determine hERG current amplitude. To evaluate hERG inhibition, blank vehicle and test samples were perfused into cells under whole-cell recording configuration via a liquid perfusion system (ALA, VM8 gravity flow delivery system). For dose-response assays, test samples were applied to cells in cumulative low to high concentrations. A positive control (dofetilide) was used in the experiments to ensure cell performance and operation as a major part of the method validation. Percentage hERG current inhibition was fitted against dose concentration to construct dose-response curves and IC 50 It was decided.

[0164] In some embodiments, the compound of the present invention is selected from the group consisting of the compounds listed in the table below.

[0165] [Table 5] TIFF0007595959000063.tif239170TIFF0007595959000064.tif239170

[0166] Clonogenic and in vivo efficacy assays method Cell Culture. MCF-7 human breast cancer cell line and HCT116 p53 wild-type and HCT116 p53- / - cell lines were obtained from ATCC. MCF7 and HCT116 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM (Gibco #11995-065). MDA-MB-231 human triple negative breast cancer cell line and FADU, human head and neck squamous cell carcinoma cell line, were obtained from Charles River Laboratories (Morrisville, NC). MDA-MB-231 cells were cultured in RPMI 1640 medium (Gibco, 11875-093). FADU cells were cultured in Minimum Essential Medium alpha (MEM alpha) (Gibco, 12571-063) supplemented with 1 mM sodium pyruvate (Gibco, 11360-070), 1X MEM non-essential amino acids (Gibco, 11140-050). All cell lines were supplemented with 10% fetal bovine serum (FBS) (Corning, 35-010-CV) and 1X They were supplemented with Antibiotic-Antimycotic (Gibco #15240-062) and cultured at 37° C., 5% CO. All cell lines were authenticated by short tandem repeat profiling and tested negative for mycoplasma.

[0167] Antibodies. Antibodies recognizing phosphorylated / activated ATM (S1981, #ab81292) and DNA-PKcs (S2056, #ab18192) were purchased from Abcam Biotechnology (Cambridge, MA). Antibodies against ATM (#A1106) and DNA-PKcs (#ab1832) were from Sigma and Abcam, respectively. Phospho-KAP1 (S824, #A300-767A) and KAP1 (A700-014) antibodies were from Bethyl Labs (Montgomery, TX). Phospho-TBK1 (#5483), cGAS (#15102), and pSTING (S366, #19781S) antibodies were from Cell Signaling Technology (CST) (Danvers, MA). STING (PA5-23381) antibody was from ThermoFisher Scientific (Waltham, MA), and actin (#A5316) antibody was from Sigma. All antibodies were diluted 1:1000 except actin, which was diluted 1:3000 in 1X TBST (1X TBS-10X TBS, (Corning, 46-012-CM), 0.05% Tween-20 (P7949) Sigma, and 1% BSA. Secondary antibodies used were: (a) Li-Cor method-goat anti-rabbit (926-3221) and goat anti-mouse (926-68020) Li-Cor, (b) ECL method: anti-rabbit IgG, HRP conjugated (#7074S), CST.

[0168] Immunoblotting. Cells were pretreated with 20, 100, 500, or 1000 nM of compound 569 or DMSO for 30 minutes as shown in Figure 1, and then irradiated with 0 or 10 Gy (XRAD 160, Precision X-Ray). In Figure 3, cells were pretreated with 1 μM of compound 569, 1 μM of ATMi (AZD0156), 1 μM of DNA-PKi (peposertib) as single agents, or with DMSO, or with ATMi and DNA-PKi in combination at 0.5 micromolar or 1 micromolar, respectively, as shown in Figure 1, for 30 minutes, and then irradiated with 0 or 10 Gy (XRAD 160, Precision X-Ray). One hour after IR, cells were lysed in RIPA buffer (50 nM Tris, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% IGEPAL® CA-630 (Sigma, I8896) in the presence of a protease and phosphatase inhibitor cocktail (Roche, #04693159001 and #04906837001) for 20 min at 4°C. Cell lysates were centrifuged at 13,200g for 10 min at 4°C and supernatants were analyzed for protein content using a BCA assay (Pierce™ BCA Protein Assay Kit, Catalog No. 23227, ThermoFisher Waltham, MA 02451) and equal amounts of protein / lane were used for subsequent immunoblot analysis. NuPAGE was performed with a final concentration of 2.5% β-mercaptoethanol. Proteins were denatured by adding LSD sample buffer [4X] (Invitrogen, NP0007) and samples were boiled for 5 min. Samples were loaded onto NuPAGE 3-8% Tris-acetate protein gels (Invitrogen, EA03785BOX) and electrophoresed in 1X Tris-acetate SDS running buffer (Invitrogen, LA0041) or loaded onto NuPAGE 4-12% Bis-Tris protein gels (Invitrogen, NP0336BOX) and electrophoresed in 1X MOPS SDS running buffer (Invitrogen, NP0001).

[0169] Proteins were transferred overnight to nitrocellulose membranes (Amersham, 10600003). Membranes were blocked with 5% nonfat dry milk in 1X TBST for 1 hour and incubated with primary antibodies overnight at 4°C. Membranes were washed 4x10 minutes with 1X TBST at RT, then incubated with secondary antibodies for 1 hour at RT, followed by washing 3x10 minutes with 1X TBST at RT. Membranes were visualized with the ODYSSEY CLX system or ECL (ECL Blotting substrate, Pierce, 32209, 34075, 34095).

[0170] Clonogenic survival assay This assay was performed with compound 569. Cells were plated in 6-well plates at different densities. 250 cells for no IR control, 5000 cells for 2Gy IR, and 10000 cells for 4Gy IR were cultured overnight. The next day, cells were preincubated with compound 569 at 100, 250, 500, or 1000 nM, or DMSO for 30 min, and then exposed to increasing doses of IR (0, 2, or 4 Gy). After IR, cells were continuously incubated with DMSO or compound 569 for 5 h, after which the medium was removed and cells were washed with PBS. Cells were cultured for 9 days in complete medium in the absence of inhibitors. Cells were then stained (PBS, 0.0037% v / v formaldehyde, 0.1% crystal violet), rinsed with water, and dried.

[0171] Tumor studies. Female NCr nu / nu mice (Crl:NU(NCr)-Foxn1nu, strain 490) were obtained from Charles River at 5–6 weeks of age. All animal procedures used in these studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Duke University.

[0172] FADU or MDA-MB-231 cells were harvested during logarithmic growth phase for in vivo implantation. Resuspended cells were washed three times with phosphate-buffered saline (PBS) and then working dilutions in PBS were prepared. FADU cells were cultured at 1x10 7Dilute MDA-MB-231 cells to 5x10 cells / mL. 7 Each mouse was injected subcutaneously into the right flank with 100 μL of the cell suspension. Tumors were at least 100 mm 3 Tumor growth was monitored until a target volume of 100 μg / kg was reached, at which point mice were randomly stratified into four treatment groups.

[0173] Following implantation of the tumor cell lines, mice were monitored weekly for tumor progression. Upon detection, tumors were measured in two dimensions using digital calipers. Tumors were measured to a size of at least 100 mm. 3 Tumors were treated after reaching a mean of 100 mg / kg / day and were measured 2-3 times weekly after enrollment in one of the treatment groups. The endpoint of the trial was defined as a 5-fold increase in tumor volume from the time of treatment.

[0174] The vehicle used in this study was 0.5% (hydroxypropyl) methylcellulose (HPMC) and 0.2% Tween 80 dissolved in deionized water. The pH of the vehicle was adjusted to 7.0-8.0, and the vehicle was stored at 4 °C. On each day of in vivo treatment, an appropriate amount of test compound was added to the vehicle at room temperature. The mixture was vortexed as necessary to produce a final concentration of 1.6 mg / mL.

[0175] Pharmacodynamic (PD) assay. Tumor studies were performed as follows: Mice bearing FADU or MDA-231 tumors were pre-administered with vehicle alone or compound 569 alone at 3, 6, and 10 mg / kg. Tumors were then irradiated with 10 Gy 45 minutes after vehicle or compound 569 administration, or left unirradiated (vehicle and compound 569 at 10 mg / kg). Tumors were harvested 1 hour after radiation.

[0176] Tissue homogenates for pharmacodynamic analysis were collected and processed as follows: Tumor tissues of FADU or MDA-MB-231 tumors were flash frozen in liquid nitrogen and ground on dry ice using a tissue grinder. A portion of the tumor powder was transferred to a microtube, followed by the addition of 500 μL of RIPA buffer [50 nM Tris, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% IGEPAL® CA-630 (Sigma, I8896)]. To 10 ml of RIPA buffer, 2 tablets each of protease inhibitor and phosphatase inhibitor (Roche, #04693159001 and #04906837001), 200 μL of 0.1 M PMSF, and 160 μL of aprotinin (Sigma, A6279) were added. The suspension was homogenized on ice with a pelletizer (KONTES) and incubated on ice for 30 min. The cell lysate was centrifuged at 13,200 rpm for 15 min at 4°C, the supernatant was transferred to a new tube, and the protein concentration was analyzed with a BCA kit (Pierce, 23227) followed by immunoblotting.

[0177] In vivo tumor growth delay studies were performed as follows: After implantation of tumor cell lines, mice were monitored once a week for tumor development. 3 As tumors developed, tumor-bearing mice were stratified into one of four groups, with five mice per group. Tumor volumes ranged from 100 to 500 mm. 3Vehicle or Compound 569 (10 mg / kg) was administered by oral gavage once daily for three consecutive days (qd x 3), alone or in combination with focal radiation. Delivery volumes of vehicle or Compound 569 were adjusted based on individual animal weight. Mice stratified into radiation therapy groups received 3 Gy per day for three consecutive days (qd x 3), 45 minutes after administration of vehicle or Compound 569. Mice were anesthetized with isoflurane during radiation therapy, which was performed with an X-RAD 225Cx small animal image-guided irradiator (precision X-ray). A 40 mm x 40 mm radiation field was positioned in the center of the tumor-bearing leg via fluoroscopy. Mice were irradiated with parallel opposed anterior-posterior fields of 225 kVp, 13 mA X-rays at an average dose rate of 300 cGy / min, using a 0.3 mm Cu filter.

[0178] Mice in Group 1 received vehicle qd x 3.

[0179] Group 2 mice received 10 mg / kg Compound 569 qd×3.

[0180] Mice in group 3 received vehicle 45 min prior to local irradiation of 3 Gy qd × 3.

[0181] Mice in group 4 received 10 mg / kg compound 569 45 min prior to 3 Gy localized irradiation qd×3.

[0182] Statistical and graphical analysis of in vivo data. For graphical presentation, Prism (GraphPad) was used. SAS 9.4 and R 3.6.1 were used for statistical analysis. Tumor growth rates were compared between the four treatment groups. Relative tumor volumes were calculated by dividing the tumor volume at each time point by the volume at baseline to adjust for different tumor sizes at the start of treatment. Line plots were used to display the median relative tumor volumes over time (Figures 6 and 8). If an animal was terminated from the study due to tumor quintupling, the final tumor volume recorded for that animal was included in the data used to calculate the median volume at the subsequent time point. Kaplan-Meier plots were used to show the proportion of mice in each treatment group remaining in the study over time (Figures 7 and 9). Mice found dead before reaching the quintupling endpoint were subject to right censoring. Differences in quintupling survival between the four treatment groups were assessed with the log-rank test. P values ​​less than 0.05 were considered statistically significant.

[0183] result Figure 1 shows an image of an immunoblot from an in vitro experiment evaluating the effect of compound 569 on MCF7 cells with or without radiation. The immunoblot shows the inhibition of radiation-induced autophosphorylation of ATM and DNA-PK kinases and radiation-induced phosphorylation of ATM substrate KAP1 by compound 569 in tumor cells. MCF7, a human breast cancer cell line, was pretreated with compound 569 at concentrations of 20, 100, 500, and 1000 nM for 30 minutes. DMSO was used as a negative control. The cells were then exposed to 0 or 10 Gy of ionizing radiation (IR), and after 1 hour, the cells were harvested for immunoblot analysis. Compound 569 showed potent dose-dependent inhibition of radiation-induced phosphorylation of DNA-PKcs at Ser2056 and ATM at Ser1981 (both autophosphorylation events) and the ATM substrate KAP1 (ser824), indicating that compound 569 inhibited both DNA-PK and ATM kinases in cells.

[0184] Figure 2 shows the radiosensitizing properties of compound 569 in an in vitro clonogenic survival assay. MCF7 cells were pretreated with vehicle or compound 569 at 100, 250, 500, or 1000 nM for 30 min and then irradiated with increasing doses of IR (0, 2, and 4 Gy). After 5 h, the medium was removed and fresh medium without inhibitors was added to the cells, which were cultured for 9 days before being fixed, stained, and colonies counted. 5 h exposure of cells to compound 569 induced a significant degree of radiosensitivity in the absence of IR in MCF7 cells, without evidence of cytotoxicity (Figure 2, Table 1).

[0185] FIG. 3 is an immunoblot showing induction of phosphorylation of TBK1 by compound 569, AZD0156 (selective ATM inhibitor; ATMi), peposertib (selective DNA-PK inhibitor; DNA-PKi), and the combination of AZD0156 and peposertib (Ai+Di) in HCT116 cells expressing wild-type p53 or that were negative for p53 expression. Phosphorylation of TBK1 is a marker of activation of the type I interferon response and is associated with enhanced tumor response to immune checkpoint blockade therapy. Dual inhibition of ATM and DNA-PKc by combining two selective chemical inhibitors together (AZD0156 and peposertib) resulted in a more profound activation of TBK1 than either of the selective inhibitors alone. Similarly, exposure of cells to compound 569, a dual inhibitor of ATM and DNA-PKcs, was a more potent activator of TBK1 phosphorylation than either of the single-targeted kinase inhibitors and was independent of p53 status. TBK1 activation by 569, as well as dual inhibition of ATM and DNA-PKcs, appeared to be independent of induction of cGAS and phospho-STING.

[0186] [ka]

[0187] To evaluate the pharmacodynamic activity of compound 569 in vivo, FADU and MDA-MB-231 cells were grown as tumor xenografts in nude mice. Vehicle or compound 569 was administered by oral gavage, alone or in combination with focal radiation. Mice were administered vehicle or compound 569 at 3, 6, and 10 mg / kg. Tumors were then either focally irradiated with 10 Gy 45 minutes later or left unirradiated (0 Gy, vehicle, and 0 Gy + 10 mg / kg compound 569). Tumors were harvested 1 hour after radiation. Immunoblotting of lysates from these tumors shows radiation-induced autophosphorylation of pDNA-PK and radiation-induced phosphorylation of KAP1, a downstream target of ATM, and dose-dependent inhibition of these phosphorylation events in FADU and MDA231 tumors treated with radiation plus compound 569. Tumor levels of radiation-induced autophosphorylation of DNA-PK and radiation-induced phosphorylation of KAP1 were significantly inhibited by approximately 55% and >80%, respectively, at 10 mg / kg (Figures 4 and 5, Tables 2-5). Basal phosphorylation of DNA-PK was also inhibited by compound 569 in tumors.

[0188] [Table 6]

[0189] [Table 7]

[0190] [Table 8]

[0191] [Table 9]

[0192] [Table 10]

[0193] FADU tumors. Mice in group 1 received vehicle, qd x 3. Aggregate tumor growth in this group was progressive. Median time to endpoint was 14 days, range 11-14 days (Figures 6 and 7). Mice in group 2 received compound 569 at a dose of 10 mg / kg, qd x 3. Median time to endpoint was 14 days, range 11-17 days. Tumor growth curves and 5-fold survival of animals in group 2 are nearly identical to animals in group 1 (Figures 6 and 7). Mice in group 3 received vehicle and a focal radiation dose of 3 Gy, delivered 45 minutes after administration of vehicle. Both vehicle and radiation were qd x 3. One animal was found dead on day 16 from unknown causes. Median time to endpoint was 21 days, range 19-25 days. Overall survival was significantly improved compared to groups 1 and 2 (P<0.01, log rank). The delay in aggregate tumor growth and the 5-fold increase in survival free for group 3 compared to groups 1 and 2 are shown in Figures 6 and 7. Mice in group 4 received compound 569 and a focal radiation dose of 3 Gy, which was delivered 45 minutes after administration of the compound. Both compound 569 and radiation were administered qdx3. The median time to endpoint was 42 days, with a range of 31-51 days. Overall survival was significantly improved compared to groups 1, 2, and 3 (P<0.01, log rank). The delay in aggregate tumor growth and the 5-fold increase in survival free for group 4 compared to all other groups are shown in Figures 6 and 7. All treatments were well tolerated.

[0194] MDA-MB-231 tumors. Mice in group 1 received vehicle, qd x 3. Median time to endpoint was 12 days, range 12-17 days. Mice in group 2 received compound 569 at a dose of 10 mg / kg, qd x 3. Median time to endpoint was 17 days, range 12-22 days. Tumor growth curves and 5-fold survival of animals in group 2 are nearly identical to animals in group 1 (Figures 8 and 9). Mice in group 3 received vehicle and a focal radiation dose of 3 Gy, which was delivered 45 minutes after administration of vehicle. Both vehicle and radiation were qd x 3. Median time to endpoint was 22 days, range 16-22 days. Overall survival was significantly improved compared to group 1 animals treated with vehicle alone (P<0.01, log rank). The 5-fold increase in survival free for group 3 compared to groups 1 and 2 is shown in Figure 9. Mice in group 4 received 10 mg / kg compound 569 and a focal radiation dose of 3 Gy, delivered 45 minutes after administration of the compound. Both compound 569 and radiation were qd x 3. One animal was found dead on day 35 from unknown causes. Median time to endpoint was 43 days, range 37-58 days. Overall survival was significantly improved compared to groups 1, 2, and 3 (P<0.01, log rank). The delay in aggregate tumor growth and the 5-fold increase in survival free for group 4 compared to all other groups are shown in Figures 8 and 9. All treatments were well tolerated.

[0195] Other embodiments Various modifications and variations of the described invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the present invention.

[0196] Other embodiments are within the claims. The present invention includes the following embodiments. (Embodiment 1) A compound of formula (I),

change

change

change

change

change

change

change

Claims

1. A compound of formula (I), 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, During the ceremony, Y is CHR 5 Or N.R. 6 and Z is CH, CR 3 or N, n is 0, 1, 2, or 3; R 1 But -O-L-N(R 7 ) 2 or an optionally substituted 4-membered saturated N-heterocyclyl; R 2 But, C 1 - 3 is alkyl, Each R 3 are independently halogen or optionally substituted C 1-3 is alkyl, R 4 is optionally substituted alkyl; R 5 is hydrogen, optionally substituted C 1-3 alkyl, or benzyloxy; R 6 is optionally substituted C 1-3 is alkyl, Each R 7 are independently H or optionally substituted C 1-3 is alkyl, The compound of formula (I), or a pharma- ceutically acceptable salt thereof, wherein L is optionally substituted ethylene.

2. 2. The compound of claim 1, wherein n is 1, or a pharma- ceutically acceptable salt thereof.

3. The compound is a compound of formula (IA), 【Chemistry 2】 2. The compound of claim 1, which is: or a pharma- ceutically acceptable salt thereof.

4. A compound of formula (IA), 【Chemistry 3】 or a pharma- ceutically acceptable salt thereof, During the ceremony, Y is CHR 5 ; R 1 is -OL-N(R 7 ) 2 ; R 2 is C 1-3 alkyl; R 3 is halogen or optionally substituted C 1-3 alkyl; R 4 is optionally substituted alkyl; R 5 is hydrogen or benzyloxy; each R 7 is independently H or optionally substituted C 1-3 alkyl; The compound of formula (IA), or a pharma- ceutically acceptable salt thereof, wherein L is optionally substituted ethylene.

5. R 3 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein is halogen.

6. 6. The compound of claim 5, or a pharma- ceutically acceptable salt thereof, wherein halogen is fluorine.

7. 2. The compound of claim 1, wherein n is 0, or a pharma- ceutically acceptable salt thereof.

8. The compound is a compound of formula (IB), 【Chemistry 4】 2. The compound of claim 1, which is: or a pharma- ceutically acceptable salt thereof.

9. R 1 But -O-L-N(R 7 ) 2 9. The compound according to any one of claims 1 to 3 and 5 to 8, which is: or a pharma- ceutically acceptable salt thereof.

10. One R 7 is H, and the remaining R 7 However, optionally C 1-3 10. The compound of any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

11. At least one R 7 The compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, wherein is isopropyl.

12. R 2 The compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, wherein is methyl, ethyl, or isopropyl.

13. R 2 The compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof, wherein is methyl.

14. R 4 The compound according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt thereof, wherein is methyl.

15. Y is CHR 5 15. The compound according to any one of claims 1 to 3 and 5 to 14, which is: or a pharma- ceutically acceptable salt thereof.

16. R 5 The compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

17. R 5 is optionally substituted C 1-3 16. The compound according to any one of claims 1 to 3 and 5 to 15, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

18. R 5 The compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, wherein is benzyloxy.

19. Y is NR 6 15. The compound according to any one of claims 1 to 3 and 5 to 14, which is: or a pharma- ceutically acceptable salt thereof.

20. R 6 is optionally substituted C 3 20. The compound of any one of claims 1 to 3, and 5 to 14, and 19, or a pharma- ceutically acceptable salt thereof, which is alkyl.

21. R 6 20. The compound according to any one of claims 1 to 3 and 5 to 14 and 19, or a pharma- ceutically acceptable salt thereof, wherein is isopropyl.

22. A compound selected from the group consisting of: 【Chemistry 5】 and pharma-ceutically acceptable salts thereof.

23. A compound of the following structure: 【Chemistry 6】 or a pharma- ceutically acceptable salt thereof.

24. A compound of the following structure: 【Chemistry 7】 or a pharma- ceutically acceptable salt thereof.

25. A compound of the following structure: 【Chemistry 8】 or a pharma- ceutically acceptable salt thereof.

26. A pharmaceutical composition comprising a compound according to any one of claims 1 to 25, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

27. ​​A pharmaceutical for use in treating a neoplastic disease in a patient in need of such treatment, comprising a compound described in any one of claims 1 to 25, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition described in claim 26.

28. The method of claim 27, wherein the patient is undergoing radiation therapy.

29. 29. The method of claim 28, wherein said compound or said pharmaceutical composition is administered to said patient simultaneously with said radiation therapy.

30. 29. The method of claim 28, wherein the compound or pharmaceutical composition is administered to the patient prior to the radiation therapy.

31. 29. The method of claim 28, wherein the compound or pharmaceutical composition is administered to the patient after the radiation therapy.

32. The method of any one of claims 28 to 31, wherein said radiation therapy comprises external, internal, brachytherapy, or total body exposure.

33. A medicament for use according to any one of claims 28 to 32, wherein said radiotherapy comprises administering an antibody-radionuclide conjugate.

34. The method for use according to any one of claims 27 to 33, wherein the patient is receiving an anti-tumor agent.

35. 35. The method of claim 34, wherein the anti-tumor agent is cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, calicheamicin, or a PARP inhibitor.

36. 36. The method of claim 35, wherein the anti-tumor agent is an anti-tumor biological agent or an anti-tumor immunotherapeutic agent.

37. The method of any one of claims 34 to 36, wherein said compound or said pharmaceutical composition is administered to said patient simultaneously with said anti-tumor agent.

38. The method of any one of claims 34 to 36, wherein said compound or said pharmaceutical composition is administered to said patient prior to said anti-tumor agent.

39. The method of any one of claims 34 to 36, wherein said compound or said pharmaceutical composition is administered to said patient after said anti-tumor agent.

40. 40. The medicament for use according to any one of claims 27 to 39, wherein the neoplastic disease is brain cancer, bladder cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gastrointestinal stromal tumor, gastric cancer, head and neck cancer, buccal cancer, oral cancer, hepatocellular carcinoma, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, salivary gland cancer, sarcoma, testicular cancer, urothelial carcinoma, vulvar cancer, or Wilms' tumor.

41. The pharmaceutical for use according to any one of claims 27 to 39, wherein the neoplastic disease is breast cancer, lung cancer, head and neck cancer, pancreatic cancer, rectal cancer, glioblastoma, hepatocellular carcinoma, cholangiocarcinoma, metastatic liver lesions, melanoma, osteosarcoma, soft tissue sarcoma, endometrial cancer, cervical cancer, prostate cancer, or Merkel cell carcinoma.

Citation Information

Patent Citations

  • Imidazo[4,5-c]quinoline as a DNA-PK inhibitor

    JP2013536256A

  • Pyrido[1,2-a]pyrimidinone analogs as mTOR / PI3K inhibitors

    JP2017518382A

  • Imidazolonyl quinolines and their use as atm kinase inhibitors

    JP2018510191A

  • Imidaz[4,5-c]quinolin-2-one compounds and their use in the treatment of cancer

    JP2019501873A